

REFERENCES

- 1- Abd El-Zaher, A.O.; Ahmed, I.T. and El-Koussi, A.D. (2001): The potential antidiabetic activity of some alpha-2-adrenoceptor antagonists. *Pharmacol. Res.*, 44 (5): 397-409.
- 2- Allain C.; Poon L.S. and Chan Richmond W. (1974): Enzymatic determination of total serum cholesterol. *Clin. Chem.*, 20: L 470-5.
- 3- Allan, D.R.; Penner S. B. and Smyth, D.D. (1993): Renal imidazoline preferring sites and solute excretion in the rat. *Br. J. Pharmacol.*, 108: 870-875.
- 4- Allan, D.R.; Penner, S. B. and Smyth, D.D. (1996): Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine. *Br. J. Pharmacol.*, 117(1): 29-34.
- 5- Amann, K.; Greber, D.; Gharehbaghi, H.; Wiest, G. and lange, B. (1992): Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. *Am. J. Hypertens.*, 5: 76-83.
- 6- Amann, K.; Nichols, C.; Tornig, Schwarz, U.; Zeier, M.; Mall, G. and Ritz, E. (1996): Effect of ramipril, nifedipine and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. *Nephrol. Dial. Transplant.*, 11(6): 1003-1011.
- 7- Amann, K.; Rump, L.C.; Simonaviciene, A.; Oberhauser, V.; Wessels, S.; Orth, S.R.; Gross, M. L.; Koch, A.; Mall, G. and Rit, E. (2000): Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotaly nephrectomized rats. *J. Am. Soc. Nephrol.*, 11(8): 1469-1478.
- 8- Ames, R. P. (1996): A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. *Am. J. Cardiol.*, 77: 12B-16B.
- 9- Anastassiadou, M.; Danoun, S.; Crane, L.; Baziard-Mouysset, G.; Payard, M. and Rettori, M.C. (2001): Synthesis and

Pharmacological evaluation of imidazoline sites I₁ and I₂ selective ligands. *Bioorg. Med. Chem.* 9(3): 585-92.

- 10- Anderson, R.J.; Hart, G.R. and Crumpler, C. P. (1981): Clonidine overdose: Report of six causes and review of the literature *Ann. Emerg. Med.*, 10: 107-112.
- 11- Angel, I.; LeRouzic, M.; Pimoule, C.; Graham, D. and Arbilla, S. (1995): [³H] cirazoline as a tool for the characterization of imidazoline sites. *Ann NY Acad. Sci.*, 763: 112-124.
- 12- Angus, J.A., Cocks, T. M. and Satoh, K. (1986): Alpha-2-adrenoceptors and endothelium-dependent relaxation in canine large arteries. *Br. J. Pharmacol.*, 88: 767-77.
- 13- Antman, E. and Smith, T.W. (1985): Digitalis toxicity. *Ann. Rev. Med.*, 36: 357.
- 14- Armah, B. I. (1987): Contribution of presynaptic α_2 -adrenoceptor stimulation to the antihypertensive action of moxonidine. *J. Cardiovasc. Pharmacol.*, 10 (Suppl.4): 581-583.
- 15- Armah, B. I. (1988): Unique presynaptic α_2 -receptor selectivity and specificity of the antihypertensive agent moxonidine. *Arzneimittel-Forschung*, 38: 1435-1442.
- 16- Armah, B. I. and Ferry, D. (1987): Moxonidine (BE 5895) is a full agonist at presynaptic (α_2) and postsynaptic (α_1) adrenoceptor sites. *Br. J. Pharmacol.*, 90 (Suppl.): 27.
- 17- Armah, B. I.; Hofferber, E. and Stenzel, W. (1988): General pharmacology of the novel centrally acting antihypertensive agent moxonidine. *Arzneimittel-Forschung* 38: 1426-1434.
- 18- Arnolda, L.; Minson, J.; Kapoor, V.; Pilowsky, P.; Llewellyn-Smith, I. and Chalmers, J. (1992): Amino acid neurotransmitters in hypertension. *Kidney Int.*, 41 (suppl 37): 52-57.
- 19- Atlas, D. (1991): Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of alpha-2-adrenergic receptor activity. *Biochem. Pharmacol.*, 41: 1541-1549.

- 20- **Baily, P. L.; Sperry, R. J. and Johnson, G. K. (1991):** Respiratory effects of clonidine alone and in combination with morphine, in humans. *Anesthesiology*, 74: 43-48.
- 21- **Bakris, G. L. and Weir, M.R. (2000):** Angiotensin-Converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern ? *Arch. Intern. Med.*, 13; 160(5): 685-693.
- 22- **Baliakina, E.V.; Patrusheva, I.F.; Rynskova, E.E. and Iurenev, A. P. (1998):** Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension. *Ter. Arkh.*, 70(1): 15-19.
- 23- **Bank, N. (1993):** Renal hemodynamic consequences of hyperlipidemia. *Miner Electrolyte Metab.*, 19: 165-172.
- 24- **Barker, W. H.; Mulloly, J. P. and Linton, K. L. P. (1998):** Trends in hypertension prevalence, treatment and control in a well-defined older population. *Hypertension*, 31: 552.
- 25- **Baron, D. N. (1989):** Lipids in: A short textbook of Chemical Pathology. The English Language Books Society.
- 26- **Bayes-Genis, A.; Guindo, J.; Vinolas, X.; Tomas, L.; Elosua, R.; Duran, I.; and Bayes de Luna, A. (1995):** Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. *Am. J. Cardiol.*, 76: 54D-59D.
- 27- **Benedict, C.R. (1999):** Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension. *Curr. Hypertens. Rep.*, 1(4): 305-312.
- 28- **Berlowitz, D.R.; Ash, A.S. and Hickey, E.C. (1998):** Inadequate management of blood pressure in a hypertensive population. *N. Eng. J. Med.*, 339: 1957.
- 29- **Bernard, J. M, Hommeril, J. L., Passuti, N. and Pinaud, M. (1991):** Postoperative analgesia by intravenous clonidine. *Anesthesiology*, 75: 577-582.
- 30- **Bernard, J. M.; Kick, O. and Bonnet, F. (1995):** Comparison of intravenous and epidural clonidine for postoperative patient-controlled analgesia. *Anesth. Analg.*, 81: 706-712.

- 31- Bidet, M.; Poujeol, P. and Parini, A. (1990): Effect of imidazolines on Na^+ transport and intracellular pH in renal proximal tubule cells. *Biochim. Biophys. Acta*, 1024: 173-178.
- 32- Bierman, E. L. and Oram, J.F. (1987): The interaction of high-density lipoproteins with extrahepatic cells. *Am. Heart. J.* 113: 549-550.
- 33- Billman, G.E. (1995): Cocaine: A review of its toxic actions on cardiac function. *Crit. Rev. Toxicol.*, 25: 113-132.
- 34- Bischoff, P.; Mahlstedt, D. and Blanc, I. (1998): Quantitative topographical electroencephalographic analysis after intravenous clonidine in healthy male volunteers. *Anesth. Analg.*, 86: 202-207.
- 35- Black, H.R. (1999): Optimal blood pressure: How low should we go? *Am. J. Hypertens.*, 12: 113S-120S.
- 36- Bock, C.; Niederhoffer, N. and Szabo, B. (1999): Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. *Naunyn-Schmiedeberg's Arch-Pharmacol.*, 359(4): 262-71.
- 37- Bockman, C.S.; Jeffries, W. B.; Pettinger, W. A. and Abdel, P.W. (1992): α_2 -adrenergic receptor subtypes on pig endothelial cell. *FASEB Journal*, 6: A 1556.
- 38- Bonnet, F.; Catoire, P. and Brun Buison, V. (1990): Clonidine-induced analgesia in postoperative patients: Epidural versus intramuscular administration. *Anesthesiology*, 72: 423-427.
- 39- Borkman, M.; Storlein, L. H.; Pan, D.A.; Jenkins, A. B.; Chisholm, D. J. and Cambell, L.V. (1993): The relationship between insulin sensitivity and the fatty-acid composition of skeletal muscle phospholipids. *N. Engl. J. Med.*, 328: 238-244.
- 40- Bouaziz H., Hewitt C. and Eisenach J.C. (1995): Subarachnoid neostigmine potentiation of alpha 2-adrenergic agonist analgesia. *Reg. Anesth.*, 20: 121-127.
- 41- Boucher, M.; Dubar, M.; Chapuy, E. and Chassaing, C. (1996): Interactions of the cardiac chronotropic effects of

- rilmenidine with the autonomic nervous system in conscious dogs: Comparison with clonidine. *J. Auton. Pharmacol.*, 16(1): 13-20.
- 42- **Bousquet, P. (1997):** Imidazoline receptors. *Neurochem. Int.*, 30(1): 3-7.
- 43- **Bousquet, P. (2000):** Identification and characterization of I₁-imidazoline receptors: their role in blood pressure regulation. *Am. J. Hypertens.*, 13(6pt 2): 84S-88S.
- 44- **Bousquet, P. (2001a):** I₁ receptors, cardiovascular function, and metabolism. *Am J. Hypertens.*, 14 (11 pt.2): 5317-5321.
- 45- **Bousquet, P. (2001b):** An attempt at cloning I₁-imidazoline receptors *J. Cardiovasc. Pharmacol.* 38(3): 335-336.
- 46- **Bousquet, P.; and Feldman, J. (1999):** Drugs acting on imidazoline receptors: A review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection. *Drugs*, 58 (5): 799-812.
- 47- **Bousquet, P.; Feldman J., Bloch, R. and Schwartz, J. (1981):** The nucleus reticularis lateralis, a region highly sensitive to clonidine. *Eur. J. Pharmacol.*, 69: 389-392.
- 48- **Bousquet, P.; Feldman, J and Schwartz, J. (1984):** Central cardiovascular effects of alpha-adrenergic drugs: Differences between catecholamines and imidazolines *J. Pharmacol. Exp. Ther.*, 230: 232-236.
- 49- **Bousquet, P., Greney, H., Bricca, G., Dontenwill, M., and Belcourt, A., (1994):** Characterization of imidazoline binding protein (s) solubilized from human brainstem: Studies with [³H] idazoxan and [³H] clonidine. *Neurochem. Int.*, 25: 183-191.
- 50- **Bousquet, P.; Bruban, V.; Schann, S. and Feldman, J. (2000):** Imidazoline receptors: A challenge. *Pharm. Acta Helv.*, 74(2-3): 205-209.
- 51- **Brater, D.C. (2000):** Pharmacology of diuretics. *Am. J. Med. Sci.*, 319(1): 38-50.
- 52- **Breckenridge, A. (1988):** Aging, Serotonin and Ketanserin. *Drugs*, 36 (Suppl. 1): 44-55.

-
- 53- **Bricca, G.; Zhang, J.; Greney, H3.; Dontenwill, M.; Stutzmann, J.; Belcourt, A. and Bousquet, P. (1993):** Heterogeneity of the [³H] idazoxan in the human cerebral cortex. *Neurochem. Int.*, 22: 153-163.
- 54- **Bricca, G.; Greney, H.; Zhang, J.; Dontenwill, M. and Stutzmann, J. (1994):** Human brain imidazoline receptors: Further characterization with [³H] clonidine. *Eur. J. Pharmacol.*, 266: 25-33.
- 55- **Brown, C. M.; Mackinnon, A.C.; Redfern, W.S.; Williams, A.; Linton, C.; Clague, R. U.; Clark, R. and Spedding, M. (1995):** RS-45041-190: A selective, high-affinity ligand for I₂-imidazoline receptors *Br. J. Pharmacol.*, 116(2): 1737-1744.
- 56- **Brown, M. J. (2001):** Matching the right drug to the right patient in essential hypertension. *Heart*, 86(1): 113-120.
- 57- **Brynne, L.; McNay, J. L.; Schaefer, H.G.; Swedberg, K.; Wiltse, C.G. and Karlsson, M. O. (2001):** Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. *Br. J. Clin. Pharmacol.*, 51(1): 35-43.
- 58- **Buerkle, H.; Schapsmeier, M.; Bantel, C.; Marcus, M.A.; Wusten, R. and Van Aken, H. (1999):** Thermal and Mechanical antinociceptive action of spinal vs peripherally administered clonidine in the rat inflamed knee joint model. *Br. J. Anaesth.*, 83 (3): 436-441.
- 59- **Burn, J. H. (1952):** Practical pharmacology Blackwell scientific publication Ltd. Oxford p.25.
- 60- **Burnier, M. and Brunne, H.R. (2000):** Angiotensin II receptor antagonists. *Lancet*, 355: 637-645.
- 61- **Byas-Smith M.G., Max, M. B. and Muir, M. (1995):** Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two stage enriched enrolment design. *Pain*, 60: 267-274.
- 62- **Campese, V. M. and Kogosov, E. (1995):** Renal afferent denervation prevents hypertension in rats with chronic renal failure. *Hypertension*, 25: 878-882.

- 53- Bricca, G.; Zhang, J.; Greney, H3.; Dontenwill, M.; Stutzmann, J.; Belcourt, A. and Bousquet, P. (1993): Heterogeneity of the [^3H] idazoxan in the human cerebral cortex. *Neurochem. Int.*, 22: 153-163.
- 54- Bricca, G.; Greney, H.; Zhang, J.; Dontenwill, M. and Stutzmann, J. (1994): Human brain imidazoline receptors: Further characterization with [^3H] clonidine. *Eur. J. Pharmacol.*, 266: 25-33.
- 55- Brown, C. M.; Mackinnon, A.C.; Redfern, W.S.; Williams, A.; Linton, C.; Clague, R. U.; Clark, R. and Spedding, M. (1995): RS-45041-190: A selective, high-affinity ligand for I₂-imidazoline receptors *Br. J. Pharmacol.*, 116(2): 1737-1744.
- 56- Brown, M. J. (2001): Matching the right drug to the right patient in essential hypertension. *Heart*, 86(1): 113-120.
- 57- Brynne, L.; McNay, J. L.; Schaefer, H.G.; Swedberg, K.; Wiltswe, C.G. and Karlsson, M. O. (2001): Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. *Br. J. Clin. Pharmacol.*, 51(1): 35-43.
- 58- Buerkle, H.; Schapsmeier, M.; Bantel, C.; Marcus, M.A.; Wusten, R. and Van Aken, H. (1999): Thermal and Mechanical antinociceptive action of spinal vs peripherally administered clonidine in the rat inflamed knee joint model. *Br. J. Anaesth.*, 83 (3): 436-441.
- 59- Burn, J. H. (1952): Practical pharmacology Blackwell scientific publication Ltd. Oxford p.25.
- 60- Burnier, M. and Brunne, H.R. (2000): Angiotensin II receptor antagonists. *Lancet*, 355: 637-645.
- 61- Byas-Smith M.G., Max, M. B. and Muir, M. (1995): Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two stage enriched enrolment design. *Pain*, 60: 267-274.
- 62- Campese, V. M. and Kogosov, E. (1995): Renal afferent denervation prevents hypertension in rats with chronic renal failure. *Hypertension*, 25: 878-882.

-
- 63- Carlisle, M.A.; Smyth, D.D. and Glavin, G. B. (1995): Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats. *J. Pharmacol. Exp. Ther.*, 274: 598-601.
- 64- Carroll, D., Jadad, A. and King, V. (1993): Single dose, randomized, double-blind, double-dummy cross-over comparison of extradural and I.V. clonidine in chronic pain. *Br. J. Anaesth.*, 71: 665-669.
- 65- Castro, M. L. and Eisenach, J.C. (1989): Pharmacokinetics and dynamics of intravenous, intrathecal and epidural clonidine in sheep. *Anesthesiology*, 71: 418-425.
- 66- Chalmers, J. P. (1999): Drug combinations for the treatment of hypertension. *International Trends in Hypertension*, 7: 7-10.
- 67- Chalmers, J. P. and Pilowsky, P. M. (1991): Brainstem and Bulbosplinal neurotransmitter systems in the control of blood pressure. *J. Hypertens.* 9: 875-694.
- 68- Chalmers, J. P. ; Arnold, L.; Kapoor, V.; Minson, J. and Pilowsky, P. (1992): Amino acid neurotransmitters in the central control of blood pressure and in experimental hypertension, *J. Hypertens.* 10 (suppl 7): 527-537.
- 69- Chalmers, M.J.; Alfred, P. and William, S.G. (1989): The nervous system and the pathogenesis of essential hypertension *Handbook of hypertension clinical aspects of essential hypertension* Robertson, JIS (ed). Amsterdam. Elsevier P. 64.
- 70- Chan, C. K. and Head, G.A. (1996): Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. *J. Hypertens.*, 14(7): 855-864.
- 71- Chan, C.K.; Sannajust, F. and Head, G.A. (1996): Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. *J. Pharmacol. Exp. Ther.*, 276 (2): 411-420.
- 72- Chan, S. L.F.; Brown, C.A.; Scarpello, K.E. and Morgan, N.G. (1995): Pancreatic beta-cells express imidazoline binding

- site that is distinct from I₁ and I₂ sites. *Ann. NY Acad. Sci.*, 763: 153-156.
- 73- **Chen M., Lee J. and Huang, B.S. (1989):** Clonidine and morphine increase atrial natriuretic peptide secretion in anaesthetized rats. *Proceedings of the Society for Experimental Biology and Medicine* 191: 299-303.
- 74- **Chrisp, P. and Faulds, D. (1992):** Moxonidine. A review of its pharmacology, and Therapeutic use in Essential Hypertension. *Drugs*, 44 (6): 993-1012.
- 75- **Cooper, K. L.; Mckiernan, J. M. and Kaplan, S.A. (1999):** Alpha-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. *Drugs*, 57: 9.
- 76- **Coote J. H. (1988):** The organization of cardiovascular neurons in the spinal cord. *Rev. Phys. Biochem. Pharmacol.*, 110: 147-285.
- 77- **Coughlan, M.G.; Lee, J.G., Bosnjak, Z. J., Schmeling, W.T. and Kampine, J. P. (1992):** Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis. *Anesthesiology*, 77: 998-1006.
- 78- **Csete, K. and Papp, J.G. (2000):** Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits. *J. Cardiovasc. Pharmacol.*, 35 (3): 417-421.
- 79- **Cuneo, R. H. and Caronna, J.J. (1987):** Neurologic complications of hypertension. *Med. Clin. North Am.*, 16: 656-620.
- 80- **Curtis, A. L. and Marwah, J. (1986):** Evidence for alpha adrenoceptor modulation of the nociceptive Jaw-Opening reflex in rats and rabbits. *J. Pharmacol. Exp. Ther.*, 238 (2): 576-579.
- 81- **Daly, P.A. and Sole, M. J. (1990):** Myocardial Catecholamines and the pathophysiology of heart failure. *Circulation*, 82 (suppl.1): I35-I43.
- 82- **Darkwa, F. K. and Smyth, D.D. (1995):** Inhibition of the natriuretic action of the imidazoline receptor agonist

- moxonidine by indomethacin in the rat. *Pharmacology*, 51: 347-355.
- 83- **Davies, K.D.; Treede, R.D. and Raja, S. N. (1991):** Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. *Pain*, 47: 309-317.
- 84- **Davis, B.R.; Vogt, T. and Frost, P. H. (1998):** Risk Factors for stroke and type of stroke in persons with isolated systolic hypertension. *Stroke*, 29: 1333.
- 85- **De Freitas, A.F. (2000):** Potential benefits of imidazoline receptors agonist drugs in treatment of systemic hypertension. *Rev Port Cardiol.*, 19(Suppl.2): 117-8.
- 86- **De Vos, H.; Bricca, G.; De Keyser, J.; De Backer, J. P.; Bousquet, P. and Vauquelin, G. (1994):** Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. *Neuroscience*, 59(3): 589-598.
- 87- **Dhir-Ravindra, N.; Dworakowski, W. and Shapiro-Bernard, H. (2002):** Meddle-age alterations in the sexually dimorphic plasma growth hormone profiles: Involvement of growth hormone-releasing factor and effects on cytochrome p450 expression. *Drug-Metab-Dispos.*, 30(2): 141-147.
- 88- **Diamant, S.; Eldar-Geva, T. and Atlas, D. (1992):** Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. *Br. J. Pharmacol.*, 106: 101-108.
- 89- **Doggrell, S.A. (2001):** Moxonidine: Some controversy. *Expert Opin Pharmacother.*, 2(2): 337-350.
- 90- **Dooley, M. and Goa, K.L. (1998):** Urapidil. Areappraisal of its use in the management of hypertension. *Drugs*, 56(5): 929-955.
- 91- **Dunne, M. J. (1991):** Block of ATP-regulated potassium channels by phentolamine and other alpha-adrenoceptor antagonists. *Br. J. Pharmacol.*, 103: 1847-1850.
- 92- **Dupuy, O.; Bauduceau, B. and Mayaudon, H. (2000):** Efficacy of rilmenidine, a selective I₁-imidazoline receptor binding

- agent in diabetic hypertensive patients. *Am. J. Hypertens.*, 13 (6 pt 2): 123S-126S.
- 93- **Dury R.A.B. and Wallington E.A. (1967):** Carleton's Histological Technique, 4th ed. Oxford University Press, Oxford, p.129.
- 94- **Dworkin, L.D.; Feiner, H.D. and Randazzo, J. (1987):** Glomerular hypertension and injury in deoxycorticosterone-salt rats on antihypertensive therapy. *Kidney Int.*, 31: 718-724.
- 95- **Dworkin, L.D.; Levin, R. I.; Benstein, J.A.; Parker, M.; Ullian, M.E. and Feiner, H. D. (1990):** Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. *Am. J. Physiol.*, 259: F598-F604.
- 96- **Eichstadt, H.; Richter, W. and Bader, M. (1989):** Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. *Cardiovasc. Drugs Ther.*, 3 (Suppl.2): 583-587.
- 97- **Eisenach, J.C. (1994):** Alpha-2-agonists and analgesia. *Exp. Opin. Invest. Drugs*, 3: 1005-1010.
- 98- **Eisenach, J.C.; Rauck, R. L.; Buzzanell, C. and Lysak, S.Z. (1989):** Epidural clonidine analgesia for intractable cancer pain: Phase I. *Anesthesiology*, 71: 647-652.
- 99- **Eisenach, J.C., Detweiler D. and Hood D. (1993):** Hemodynamic and analgesic actions of epidurally administered clonidine. *Anesthesiology*, 78: 277-287.
- 100- **Eisenach, J.C.; Dupen, S. and Dubois, N. (1995):** Epidural clonidine analgesia for intractable cancer pain. *Pain*, 61: 391-399.
- 101- **Eisenach, J.C., Dekock M. and Klimscha (1996):** Alpha-2 adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). *Anesthesiology*, 85: 655-674.
- 102- **El-Ayoubi, R.; Gutkowska, J.; Regunathan, S. and Mukaddam-Daher, S. (2002):** Imidazoline receptors in the heart: Characterization, Distribution, and regulation. *J. Cardiovasc. Pharmacol.*, 39(6): 875-883.

-
- 103- **Elisaf, M.S.; Petris, C.; Bairaktari, E. and Karabina, S.A. (1999):** The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. *J. Hum. Hypertens.*, 13(11): 781-5.
- 104- **Elliott, H. L. (1998):** Moxonidine: Pharmacology, clinical pharmacology and clinical profile. *Blood-Press.*, (Suppl.3): 23-27.
- 105- **Erdinçler, D.S.; Seven, A.; Inci, F. Beger T. and Candan G. (1997):** Lipid peroxidation and Antioxidant status in experimental animals: Effect of aging and hypercholesterolemic diet. *Clinica. Chimica. Acta*, 265: 77-84.
- 106- **Ernsberger, B. (1990):** Moxonidine, a second-generation centrally-acting antihypertensive binds selectively to imidazole sites in the ventrolateral medulla (VLM) and kidney. *Pharmacologist*, 32: 191.
- 107- **Ernsberger, P. (1992):** Heterogeneity of imidazoline binding sites: Proposed I₁ and I₂ subtypes. *Fund. Clin. Pharmacol.*, 6 (Suppl.1); 55.
- 108- **Ernsberger, P. (1998):** The I₁-imidazoline receptor agonist moxonidine: Molecular, Cellular and organismic actions. *Rev. Contemp. Pharmacother.*, 9: 441-462.
- 109- **Ernsberger, P. (2000):** Pharmacology of moxonidine: an I₁-imidazoline receptor agonist, *J. Cardiovasc. Pharmacol.*, 35(7 Suppl.4): S 27-S41.
- 110- **Ernsberger, P.; Meeley, M.P.; Mann, J.J. and Reis, D. J. (1987):** Clonidine binds to imidazole binding sites as well as alpha₂-adrenoceptors in the ventrolateral medulla. *Eur. J. Pharmacol.*, 134: 1-13.
- 111- **Ernsberger, P.; Giuliano, R.; Willette, R. N. and Reis, D. J. (1990):** Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. *J. Pharmacol. Exp. Ther.*, 253: 408-418.
- 112- **Ernsberger, P.; Westbrook, K. L.; Christen, M. O. and Schafer, S.G. (1992):** A second generation of centrally

- acting antihypertensive agents act on putative I₁-imidazoline receptors. *J. Cardiovasc. Pharmacol.*, 20 (Suppl. 4): S 1-S10.
- 113- **Ernsberger, P.; Damon, T. H.; Graff, L. M.; Schafer, S.G. and Christen, M. O. (1993):** Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I₁-imidazoline sites. *J. Pharmacol. Exp. Ther.*, 264: 172-182.
- 114- **Ernsberger, P.; Graves, M.E. and Graff, L. M. (1995):** I₁-imidazoline receptors: definition, characterization, distribution and transmembrane signaling. *Ann. NY Acad. Sci.*, 763: 22-42.
- 115- **Ernsberger, P.; Kolestsky, R. J.; Collins, L.A. and Bedol, D. (1996):** Sympathetic nervous system in salt-sensitive and obese hypertension amelioration of multiple abnormalities by a central sympatholytic agent. *Cardiovasc Drugs Ther.*, 10 (suppl.1): 275-282.
- 116- **Ernsberger, P.; Freidman, J.E.L and Koletsky, R. J. (1997):** The I₁-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease *J. Hypertens.*, 15(1): 59-523.
- 117- **Ernsberger, P.; Kolestsky, R.J. and Friedman, J.E. (1998):** Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease. *Rev. Contemp. Pharmacother.*, 9: 411-428.
- 118- **Ernsberger, P.; Koletsky, R. J. and Friedman, J.E. (1999):** Molecular pathology in the obese spontaneous hypertensive koletsky rat: A model of syndrom X. *Ann N Y Acad Sci.*, 18; 892: 272-288.
- 119- **Escriba, P.V.; Sastre, M.; Wang, H.; Regunathan, S. ; Reis, D. J., and Garcia-Sevilla, J.A. (1994):** Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. *Neurosci. Lett.*, 178: 81-84.
- 120- **Esler, M. (2000):** The sympathetic system and hypertension. *Am. J. Hypertens.*, 13 (6 pt 2): 599-5105.
- 121- **Esler, M. and Kaye, D. (1998):** Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. *J. Auton. Nerv. Syst.*, 15; 72(2-3): 210-9.

- 122- Esler, M.; Rumantir, M.; Wiesner, G.; Kaye, D.; Hastings, J. and Lambert, G. (2001): Sympathetic nervous system and insulin resistance: From obesity to diabetes. *Am. J. Hypertens.*, 14 (11 pt 2): 5304-5309.
- 123- Fairbanks, C.A. and Wilcox, G. L. (1999): Moxonidine, A selective α_2 -adrenergic and imidazoline-receptor agonist, produces spinal antinociception in mice. *J. Pharmacol. Exp. Ther.*, 290(1): 403-412.
- 124- Fairbanks, C.A.; Nguyen, H. O; Grocholski, B. M. and Wilcox, G. L. (2000a): Moxonidine, a selective imidazoline- α_2 -adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice. *Anesthesiology*, 93(3): 765-773.
- 125- Fairbanks, C.A.; Posthumus, I. J.; Kitto, K.F.; Stone, L.S. and Wilcox, G. L. (2000b): Moxonidine, a selective imidazoline- α_2 -adrenergic receptor agonist, synergize with morphine and deltorphin II to inhibit substance p-induced behaviour in mice. *Pain*, 84(1): 13-20.
- 126- Fairbanks, C.A.; Stone, L.S.; Kitto, K.F.; Nguyen, H. O.; Posthumus, I. J. and Wilcox, G. L. (2002): Alpha (2C)-adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. *J. Pharmacol. Exp. Ther.*, 300(1): 282-290.
- 127- Fauvel, J. P.; Najem, R.; Maakel, N.; Pozet, N. and Laville, M. (1998): Effects of moxonidine on stress-induced peak blood pressure and renal function: a randomized, double-blind, placebo-controlled crossover study. *J. Cardiovasc. Pharmacol.*, 32: 495-499.
- 128- Fedida, D. and Bouchard, R.A. (1992): Mechanisms for the positive inotropic effect of α_1 -adrenoceptor stimulation in rat cardiac myocytes. *Circ. Res.*, 71: 673-688.
- 129- Ferder, L.; Inserra, F.; Ryba, D.; Daccordi, H. and Lipszyc, P. (1989): Renal function in patients with type IIa and IIb hyperlipidemia. *ASN*. 86a (abstract).
- 130- Ferreira, S. H. (2000): Angiotensin converting enzyme: history and relevance. *Semin-Perinatol.*, 24(1): 7-10.

- 131- **Feuring, M.; Cassel, W. and Thun, B. (2000):** Moxonidine in patients with arterial hypertension and chronic obstructive pulmonary disease. *Clin. Drug Invest.*, 20: 19-24.
- 132- **Fields H.L. and Basaum A. I. (1978):** Brainstem control of spinal neurons. *Ann. Rev. Physiol.*, 40: 217-248.
- 133- **Fogari, R. and Zoppi, A. (2002):** Effects of antihypertensive therapy on sexual activity in hypertensive men. *Curr. Hypertens. Rep.*, 4(3): 202-10.
- 134- **Fossati, P. (1982):** Enzymatic colorimetric determination of serum triglycerides. *Clin. Chem.*, 28: 2077.
- 135- **Fozard, J.R.; Mir, A. K. and Middlemiss, D. N. (1987):** Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. *J. Cardiovasc. Pharmacol.*, 9: 328-347.
- 136- **Frank, T.; Thieme, V. and Radowm, L. (2000):** Premedication in maxillofacial surgery under total intravenous anesthesia. Effects of clonidine compared to midazolam on the perioperative course. *Anesthesiol Intensivmed Notfallmed Schmerzther*, 35: 428-434.
- 137- **Frei, M.; Kuster, L.; Gardosch-Von-Krosigk, P.P.; Koch, H.F. and Kuppers, H. (1994):** Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect. *J. Cardiovasc. Pharmacol*, 24 (Suppl.1): S 25-S28.
- 138- **French, S.W.; Yamanaka, W. and Ostwald, R. (1967):** Dietary induced glomerulosclerosis in the guinea-pig. *Arch. Pathol.* 83: 204-210.
- 139- **Friedewald, W.T. et al. (1972):** *Clin. Chem.*, 18: 499-512.
- 140- **Friedman, J.E.; Ishizuka, T.; Liu, S.; Farrell, C.J. and Koletsky, R. J. (1998):** Anti-Hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. *Blood press.*, 7 (Suppl. 3): 32-39.

- 141- **Frisk-Holmberg, M. and Planitz, V. (1987):** A selective alpha-2-adrenoceptor agonist in arterial essential hypertension. Clinical experience with moxonidine. *Current Therapeutic Research*, 42: 138-146.
- 142- **Fujita, K.; Matsumura, Y.; Kita, S.; Miyazaki, Y.; Hisaki, K.; Takaoka, M. and Morimoto, S. (1995):** Role of endothelin-1 and ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. *Br. J. Pharmacol.*, 114: 925-930.
- 143- **Furchgott, R.F. and Bhadrakom, S. (1953):** Reaction of strips of rabbit aorta to epinephrine, isoproterenol, sodium nitrite and other drugs. *J. Pharmacol. Exp. Ther.*, 108: 129-143.
- 144- **Furst, S. (1999):** Transmitters involved in antinociception in the spinal cord. *Brain Res. Bull.*, 15; 48 (2): 129-141.
- 145- **Galle, J.; Schollmeyer, P. and Wanner, C. (1993):** Cyclosporin and oxidized low-density lipoproteins synergistically potentiate vasoconstriction: influence of the endothelium. *Eur. Heart. J.*, 14, Suppl. 1: 111-117.
- 146- **Garcia-Sevilla, J.A.; Sastre, M. and Escriba, P.V. (1995):** Age dependent increases of immunoreactive imidazoline receptors in the human brain: possible association of a 29/30 Kda protein with the I₂-imidazoline receptor identified by [³H] idazoxan. *Neurosci. Lett*, 23; 184 (2): 133-136.
- 147- **Garcia-Sevilla, J.A.; Escriba, P.V. and Guimon, J. (1999):** Imidazoline receptors and human brain disorders. *Ann. N.Y Acad. Sci.*, 21, 881: 392-409.
- 148- **Gavras, H.; Brunner, H.R., Laragh, J. H.; Vaughan, E.D.; Koss, M.; Cote, L. J. and Gavras, I. (1975):** Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. *Circ. Res.*, 36: 300-309.
- 149- **Gillis, R.A. and Quest, J.A. (1979):** The role of the nervous system in the cardiovascular effects of digitalis. *Pharmac. Rev.*, 31: 19-97.
- 150- **Gillis, R.A.; Kellar, K. J. and Quest, J.A. (1988):** Experimental studies on the neurocardiovascular effect of urapidil. *Drugs*, 35 (Suppl.6): 20-33.

-
- 151- Glavin, G. B. and Smyth, D.D. (1995a): Effects of the selective I₁-imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats. *Br. J. Pharmacol.*, 114: 751-754.
- 152- Glavin, G. B. and Smyth, D.D. (1995b): Moxonidine decreases gastric secretion and gastric mucosal injury in rats. *Ann. NY Acad. Sci.*, 763: 433-435.
- 153- Glynn, C. and O'Sullivan K. (1995): A double-blind randomized comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. *Pain*, 64: 337-343.
- 154- Goldstone, L.A. (1983): *Understanding medical statistics*. William Heinmann Medical Books Limited, London.
- 155- Göthert, M. and Molderings, G. J. (1991): Involvement of presynaptic imidazoline receptors in the alpha-2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives. *Naunyn Schmiedebergs Arch. Pharmacol.*, 343(3): 271-282.
- 156- Göthert, M. and Molderings, G. J. (1992): Modulation of norepinephrine release in blood vessels: Mediation by presynaptic imidazoline receptors and α_2 -adrenoceptors. *J. Cardiovasc. pharmacol.*, 20 (Suppl. 4): 516-520.
- 157- Göthert, M. and Molderings, G. J. (1998): Presynaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. *Fundam. Clin. Pharmacol.*, 12(4): 388-397.
- 158- Göthert, M.; Bruss, M.; Bonisch, H. and Molderings, G. J. (1999): Presynaptic imidazoline receptors. New Developments in characterization and classification. *Ann. N Y Acad. Sci.*, 21; 881: 171-184.
- 159- Gowing, L.; Ali, R. and White, J. (2000): Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. *Cochrane-Database-Syst Rev.*, (2): CD 002021 (Abstract).
- 160- Grant, J.A. and Scrutton, M.C. (1980): Interaction of selective α_2 -adrenoceptor agonists and antagonists with human and rabbit blood platelets. *Br. J. Pharmacol.*, 71: 121-134.

- 161- **Grassi, G.; Turri, C. and Dell'Oro, R. (1998):** Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. *J. Hypertens.*, 16: 1789.
- 162- **Grassi, G.; Turri, C.; Seravalle, G.; Bertinieri, G.; Pierini, A. and Mance, G. (2001):** Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. *Hypertension*, 38(2): 286-91.
- 163- **Gray, A. M.; Pache, D. M. and Sewell, R.D. (1999):** Do alpha-2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? *Eur. J. Pharmacol.*, 6; 378(2): 161-168.
- 164- **Greenwood, J. P.; Scott, E. M.; Stoker, J. B. and Mary, D.A. (2000):** Chronic I₁-imidazoline agonism: Sympathetic mechanisms in hypertension. *Hypertension*, 35 (5): 1264-1269.
- 165- **Grenay, H.; Ronde, P.; Magnier, C.; Maranca, F.; Rascente, C.; Quaglia, W.; Lugnier, C. and Bousquet, P. (2000):** Coupling of I₁-imidazoline receptors to the CAMP pathway: studies with a high selective ligand. *Benzoline. Mol. Pharmacol.*, 57(6): 1142-51.
- 166- **Greven, J. and Von Bronewski-Schwarzer, B. (2001):** Site of action of moxonidine in the rat nephron. *Naunyn. Schmiedebergs Arch Pharmacol.* 364(6): 496-500.
- 167- **Gross, F. (1950):** Von Desoxycorticosterone acetate kochsalzouf den, experimentellen hochdruck der ratte. *Arch. Int. Pharmacodyn.*, 81: 211-221.
- 168- **Gross, G.; Hanft, G. and Kolassa, N. (1987):** Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxy-tryptamine (5-HT) binding sites of the 5-HT_{1A}-subtype and for α_1 -adrenoceptor binding sites. *NS Arch. Pharmacol.*, 336: 597-601.
- 169- **Grundy, S. M. (1997):** Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. *Circulation*, 95: 1-4.

- 170- Guo, X. and Dick, L. (1999): Late onset angiotensin-Converting enzyme induced angioedema: Case report and review of the literature J. Okla. State Med. Assoc., 92(2): 71-73.
- 171- Guyenet, P.G. (1997): Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites? Am. J. Physiol., 273: R1580-1584.
- 172- Haberland, M.E. and Fogelman, A. M. (1987): The role of altered lipoproteins in the pathogenesis of atherosclerosis, Am. Heart J., 113: 573-577.
- 173- Haenni, A. and Lithell, H. (1999): Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J. Hypertens., 17 (Suppl.3): 529-539.
- 174- Haider, A.W.; Chen, L. and Larson, M.G. (1997): Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infraction. Hypertension, 30: 1020.
- 175- Hall, J.E.; Guyton, A.C. and Mizelle, H. L. (1990): Role of renin angiotensin system in control of sodium secretion and arterial pressure. Acta Physiol. Scand. Suppl., 591: 48-62.
- 176- Hall J.E., Uhrich T. P. and Ebert T. J. (2001): Sedative, analgesic, and cognitive effect of clonidine infusions in humans. Br. J. Anaesth., 86: 5-11.
- 177- Hamilton, C.A.; Yakubu, M.A.; Jardine, E. and Reid, J. L. (1991): Imidazoline binding sites in rabbit kidney and forebrain membranes. J. Auton. Pharmacol., 11: 277-283.
- 178- Hansson, L.; Lindholm, L. H. and Niskanen, L. (1999): Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention project randomised trial. Lancet, 353: 611-616.
- 179- Hansson, L.; Hedner, T. and Lund-Johnsen, P. (2000): Randomised trial of the effect of calcium antgonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension. Lancet, 356: 359-365.

- 180- Hauser, W.; Gutting, J.; Nguyen, T. and Dominiak, P. (1995): Influence of imidazoline on catecholamine release in pithed spontaneously hypertensive rats. *Ann. NY Acad. Sci.*, 763: 573-579.
- 181- Haxhiu M.A., Dreshaj I.A., Schafer S.G. and Ernsberger P. (1994): Selective antihypertensive action of moxonidine is mediated mainly by I₁-imidazoline receptors in the rostral ventrolateral medulla. *J. Cardiovasc. Pharmacol.*, 24 (suppl.1) 51-58.
- 182- Haxhiu, M.A.; Dreshaj, I.A.; Erokwu, B.; Collins, L.A. and Ernsberger, P. (1995): Effect of I₁-imidazoline receptor activation on responses of hypoglossal and phrenic nerve to chemical stimulation. *Ann. N.Y. Acad. Sci.*, 763: 445-62.
- 183- Hayashi, Y.; Sumikawa, K.; Maze, M.; Yamatodani, A.; Kamibayashi, T.; Kuro, M. and Yoshiya, I. (1991): Dexmedetomidine prevents epinephrine-induced arrhythmias through stimulation of central α_2 -adrenoceptors in halothane-anesthetized dogs. *Anesthesiology*, 75: 113-117.
- 184- Hayashi, Y.; Kamibayashi, T.; Maze, M.; Yamatodani, A.; Sumikawa, K.; Kuro, M. and Yoshiya, I. (1993): Role of imidazoline-preferring receptors in the genesis of epinephrine-induced arrhythmias in halothane-anesthetized dogs. *Anesthesiology*, 78: 524-530.
- 185- Hayar, A. and Guyenet, P.G. (2000): Prototypical imidazoline-1 receptor ligand moxonidine activates alpha-2-adrenoceptors in bulbospinal neurons of the RVLM. *J. Neurophysiol.*, 83 (2): 766-776.
- 186- Haywood, J.R.; Sahffer, R.A. and Fastenow, C. (1981): Regional blood flow measurements with pulsed doppler flowmeter in conscious rats. *Am. J. Physiol.*, 241: H273-H278.
- 187- He, M. M.; Abraham, T. L.; Lindsay, T. J.; Schaefer, H.C.; Pouliquen, I. J.; Payne, C.; Czeskis, B. and Mitchell, M. I. (2003): Metabolism and disposition of the antihypertensive agent moxonidine in humans. *Drug Metab. Dispos.*, 31(3): 334-342.

- 188- Head, G.A. and Burke, S. L. (2000): I₁-imidazoline receptors in cardiovascular regulation: The place of rilmenidine. *Am. J. Hypertens.*, 13(6 pt2): 89S-98S.
- 189- Head, G.A.; Burke, S. L. and Sannajust, F. J. (2001): Involvement of imidazoline receptors in the baroreflex effects of rilmenidine in conscious rabbits. *J. Hypertens.*, 19(9): 1615-1654.
- 190- Hein, L. (2001): The alpha-2-adrenergic receptors: Molecular structure and in vivo function. *Z-Kardiol*, 90 (9): 607-612.
- 191- Henriksen, E. J.; Jacob, S.; Fogt, D. L.; Young blood, E. B. and Godicke, J. (1997): Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. *Hypertension*, 30: 1560-1565.
- 192- Herman, Z.S. (1997): Agmatine: A novel endogenous ligand of imidazoline receptors. *Pol. J. Pharmacol.*, 49(2-3): 85-88.
- 193- Hieble, J. P. and Ruffolo, R.R. (1995): Possible structural and functional relationship between imidazoline receptors and alpha-2-adrenoceptors. *Ann. N Y Acad. Sci.*, 12; 763: 8-21.
- 194- Hill, G.S. and Heptinstall, R. H. (1968): Steroid induced hypertension in the rat. *Am. J. Pathol.*, 52: 1-20.
- 195- Hjermann, I. (1992): The metabolic cardiovascular syndrome: Syndrome X, Reaven's syndrome, Insulin Resistance Syndrome, Atherothrombogenic Syndrome. *J. Cardiovasc. Pharmacol.*, 20 (Suppl.8): 55-510.
- 196- Hohage, H.; Hess, K.; Jahl, C.; Greven, J. and Schlatter, E. (1997a): Renal and blood pressure effects of moxonidine and clonidine in spontaneously hypertensive rats. *Clinical Nephrology*, 48(6): 346-352.
- 197- Hohage, H.; Schlatter, E and Greven, J. (1997b): Effects of moxonidine and clonidine on renal function and blood pressure in anesthetized rats. *Clinical Nephrology*, 47 (5): 316-324.
- 198- Hondeghem, L. M., and Roden, D. M. (1998): Agents used in cardiac arrhythmias. In: *Basic and Clinical pharmacology*.

- Katzung BGP (ed.), Applton and Lange, California. P.216-241.
- 199- **Horn, E. P.; Werner, C.; Sessler, D. I. and Steinfath, M. (1997):** Late intraoperative clonidine administration prevents postanesthetic shivering after total intravenous or volatile anesthesia. *Anesthesia and Analgesia.*, 84: 613-617.
- 200- **HOUOT, O. (1985):** Interpretation of clinical laboratory tests. Siest, G.; Henny, J.; Schiele, F. and Young, D.S. (Eds), Biomedical Publications. pp.220-234.
- 201- **Howe J.R., Wan J. Y. and Yaksh T. L. (1983):** Selective antagonism of the antinociceptive effect of intrathecally applied alpha adrenergic agonists by intrathecal prazosin and intrathecal yohimbine. *J. Pharmacol. Exp. Ther.*, 224: 552-558.
- 202- **Hunter, D. J.; Fontana, L.R.; Hedley, J.R.; Jasper, R.; Lewis, R.E.; Link, R. and Secchi, J. (1997):** Assessment of the role of α_2 -adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. *Br. J. Pharmacol.*, 122: 1339-1344.
- 203- **Iriuchijima, J. (1999):** Vascular areas where clonidine induces vasodilation in hypertensive and normotensive rats. *Tohoku. J. Exp. Med.*, 189(1): 29-36.
- 204- **Irzyniec, T.; Mall, G.; Greber, D. and Ritz, E. (1992):** Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. *Am. J. Hypertens.*, 5: 437-443.
- 205- **Ivanova, I. L.; Shchepin, V.A. and Akulin, V.N. (1986):** Therapeutic effect of lipids from the Far Eastern sardine in experimental hypercholesterolemia in rats. *Vopr. Pitan.*, 4: 48-50.
- 206- **Iwamoto, K.; Chen, C. and Kato, L. (1987):** Effects of urethane anaesthesia and age on organ blood flow in rats measured by hydrogen gas clearance method. *J. Pharmacobiodyn.*, 10(6): 280-289.

- 207- **Jackson, H.C.; Griffin I.J. and Nutt, D. J. (1991):** The effect of idazoxan and other α_2 -adrenoceptor antagonists on food and water intake in the rat. *Br. J. Pharmacol.*, 104: 258-262.
- 208- **Jacob, I. H. and Kenmeth D. K., (1972):** Protection against epinephrine-induced myocardial necrosis by drugs that inhibit platelet aggregation *Am. J. Cardio.*, 30: 838-845.
- 209- **Jager, B.; Verboom, C. and Brunner, H. (1998):** The clinical efficacy of moxonidine in hypertension. *Rev. Contemp. Pharmacother.*, 9: 463-471.
- 210- **Jain, S.; Malhotra, P.; Kumari, S. and Varma, S. (2001):** Safety and efficacy of moxonidine in mild to moderate hypertension *J. Assoc. Physicians. India*, 49: 829-830.
- 211- **Janssen, B. J.; Lukoshkova, E.V. and Head, G.A. (2002):** Sympathetic modulation of renal blood flow by rilmenidine and captopril: Central vs. Peripheral effects. *Am. J. Physiol. Renal. Physiol.*, 282 (1): F113-123.
- 212- **Jarvis, D.A.; Duncan, S.R. and Segal, I.S. (1992):** Ventilatory effects of clonidine alone and in presence of alfentanil, in human volunteers. *Anesthesiology*, 76: 899-905.
- 213- **Joint National Committee (1997):** The sixth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (JNC VI). *Arch Intern. Med.*; 157: 2413-2446.
- 214- **Jonas, J.C.; Plant, T.D. and Henquin, J.C. (1992):** Imidazoline antagonists of alpha-2 adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K^+ channels in pancreatic beta-cells. *Br. J. Pharmacol.*, 107: 8-14.
- 215- **Jong, Ph.; Demers, C.; McKelvie, R.S. and Liu, P. P. (2002):** Angiotensin receptor blockers in heart failure: Meta-Analysis of randomized controlled trials. *J. Am. Coll. Cardiol.*, 6, 39 (3): 463-470.
- 216- **Julius, S. (1996):** The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. *Clin. Exp. Hypertens.*, 18: 305-321.

- 217- **Kahan, T. (1998):** The importance of left ventricular hypertrophy in human hypertension *J. Hypertens.*, 16 (suppl): 23.
- 218- **Kaplan, N. M. (2000):** Diuretics as a basis of antihypertensive therapy. An overview. *Drugs*, 59 (Suppl 2): 21-25.
- 219- **Kaplan, N. M. (2001):** Systemic hypertension: Mechanisms and diagnosis. In *Heart Disease. A textbook of cardiovascular medicine*, Braunwald, E.; Zipes, D. P. and Libby, P. (Eds), 6th edition, Saunders Company, Philadelphia. pp. 941-971.
- 220- **Kaplan, R; Aynedjian, H.S.; Schlondorff, D. and Bank, N. (1990):** Renal vasoconstriction caused by short-Term cholesterol feeding is corrected by thromboxane antagonist or probucol. *J. Clin. Invest.*, 86: 1707-1714.
- 221- **Karam, H.; Clozel, J. P.; Bruneval, P.; Gonzalez, M.F. and Menard, J. (1999):** Contrasting effects of selective T- and L- type calcium channel blockade on glomerular damage in DOCA-hypertensive rats. *Hypertension*, 34: 673-678.
- 222- **Keane, W.F.; Kasiske, B. L. and O'Donnell, M. P. (1988):** Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. *Am. J. Nephrol.*, 8: 261-271.
- 223- **Kentera, D.; Susic, D.; Veljkovic, V. and Zdravkovic M. (1987):** Ouabain-arrhythmogenicity in hypertrophied right and left ventricle of the rat. *Basic Res. Cardiol.* 82 (3): 241-245.
- 224- **Khan, Z. P.; Ferguson, C. N.; Jones, R. M. (1999):** Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. *Anaesthesia*, 54: 146-165.
- 225- **Khokhlova, O. N.; Murasher, A. N.; Lavrova, L. N. and Medvedev, O.S. (2000):** Effects of chronic administration of moxonidine in hypertensive rats. *Eksp Klin Farmakol.*, 63(5): 21-3.
- 226- **Khokhlova, O. N.; Murashev, A. N. and Medvedev, O.S. (2001):** Role of the rostroventrolateral medulla in moxonidine induced changes in cardiochronotropic regulation. *Bull. Exp. Biol. Med.*, 132 (5): 1073-1075.

- 227- Kirch, W.; Hutt, H. J. and Planitz, V. (1988): The influence of renal function on clinical pharmacokinetics of moxonidine. *Clin. Pharmacokinet.*, 15: 245-253.
- 228- Kirch, W.; Hutt, H.J. and Planitz, V. (1990): Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. *J. Clin. Pharmacol.*, 30: 1088-1095.
- 229- Kita T., Kagawa K and Mammoto T. (2000): Supraspinal, not spinal, alpha-2 adrenoceptors are involved in the anesthetic-sparing and hemodynamic-stabilizing effects of systemic clonidine in rats. *Anesth Analg.*, 90: 722-726.
- 230- Klag, M. J.; Whelton P. K. and Randall, B. L. (1997): End-Stage renal disease in African-American and White men. *JAMA*, 277: 1293.
- 231- Klimscha W., Tong C. and Eisenach J.C. (1997): Intrathecal alpha-2 adrenergic agonists stimulate acetylcholine and norepinephrine release from spinal cord dorsal horn in sheep. An in Unio microdialysis study. *Anesthesiology*, 87: 110-116.
- 232- Klink, F. (1987): Clinical investigation of the passage of moxonidine from the maternal blood stream to breast within patients with hypertension. Study K. 220-5918. Hannover: Solvay pharmaceuticals.
- 233- Koepke, J. P.; Jones, S. and Dibona, G.F. (1987): Alpha-2-adrenoceptors in arrygdala control renal sympathetic nerve activity and renal function in conscious spontaneously hypertensive rats. *Brain Res.*, 404: 80-88.
- 234- Kover, G.; Tost, H. and Darvasi, A. (1989): The effects of clonidine on the kidney function in the anesthetized dog. *Acta. Physiol. Hung.*, 74 (3-4): 229-241.
- 235- Kraft, K. and Vetter, H. (1994): Twenty-four-hour blood pressure profiles, in patients with mild-to-moderate hypertension. Moxonidine versus captopril. *J. Cardiovasc Pharmacol.*, 24 (Suppl.1): 529-535.

- 236- **Krauss, R. M. (1987):** Relationship of intermediate and low density lipoprotein subspecies to risk of coronary artery disease. *Am. Heart. J.*, 113: 578-582.
- 237- **Krum, H. (1999):** Sympathetic activation and the role of beta-blockers in chronic heart failure. *N.Z.J. Med.*, 29(3): 418-427.
- 238- **Kuzmin, A. I.; Lodygin, D. N.; Kalenikova, E. I.; Bychkova, E. and Khokhlova O. N. (2000):** Pharmacological analysis of the role of central alpha-2-adrenergic and imidazoline receptors in mechanism of the hypotensive effect of clonidine in rats. *Eksp. Klin. Farmakol.*, 63(4): 24-8.
- 239- **Lachaud-Pettiti, V., Poderin, R.A., Chretien, Y. and Parini, A. (1991):** Imidazoline-Guanidinium and Alpha 2-adrenergic binding sites in basolateral membranes from human kidney. *Eur. J. Pharmacol.*, 206: 23-31.
- 240- **Langer, S.Z.; Shepperson, M. B. and Massingham, R. (1981):** Preferential noradrenergic innervation of alpha-₁-adrenergic receptors in vascular smooth muscle. *Hypertension*, 3(1): 112-118.
- 241- **Langin, D.; Paris, H. and Lafontan, M. (1990):** Binding of [³H] idazoxan and of its methoxy derivative [³H] RX 821002 in human fat cells: [³H] idazoxan but not [³H] RX 821002 labels additional non-alpha-2-adrenergic binding sites. *Mol. Pharmacol.*, 37: 876-885.
- 242- **Lanier, S. M.; Ivkovic, B.; Singh, I.; Neumeyer, J. L. and Bakthavachalam, V. (1993):** Visulization of multiple imidazoline / guanidinium-receptive sites. *J. Biol. Chem.*, 268: 16047-51.
- 243- **Leaes, C.G. and Rosito, G.A. (1998):** Moxonidine. A new antihypertensive agent of central action. *Arq. Bras. Cardiol.*, 70(6): 443-448.
- 244- **Leiphart J.W., Cynthia V. and Dills BS (1995):** A comparison of intrathecally administered narcotic and non-narcotic analgesics for experimental chronic neuropathic pain. *J. Neurosurg.*, 82: 595-599.

- 245- **Leonetti, G. (1988):** Centrally acting antihypertensive agents. *J. Cardiovasc. Pharmacol.*, 12 (Suppl. 8): 568-573.
- 246- **Lepran, I. and Papp, P.J. (1994):** Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion *J. Cardiovasc. Pharmacol.*, 24 (Suppl.1): S9-S15.
- 247- **Li, G.; Regunathan S.; Barrow C.J.; Cooper R. and Reis D. J. (1994):** Agmatine: An endogenous clonidine displacing substance in the brain. *Science*, 263: 966-9.
- 248- **Limon, I., Couprie, I., Lanier, S. M. and Parini, A., (1992):** Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney. *J. Biol. Chem.*, 267: 2165-49.
- 249- **London, G. M.; Safar, M.E.; Sassard, J.E.; Levenson, J.A. and Simon, A.C. (1984):** Renal and Systemic hemodynamics in sustained essential hypertension. *Hypertension*, 6(5): 743-754.
- 250- **Lopes-Virella, M.F., et al. (1977).** *Clin. Chem.*, 23: 882.
- 251- **Ma, L. and Fogo, A. B. (2001):** Role of angiotensin II in glomerular injury. *Semin-Nephrol.*, 21(6): 544-553.
- 252- **Mackay, F. J.; Pearce, G. L. and Mann. R.D. (1999):** Cough and angiotensin II receptor antagonists : Cause or confounding? *Br. J. Clin. Pharmacol.*, 47 (1): 111-114.
- 253- **Mackenzie, H.S.; Ziai, F.; Omer, S.A.; Nadim, M. K. and Taal, M.W. (1999):** Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. *J. Am. Soc. Nephrol.*, 10 (Suppl.12) S 283- S286.
- 254- **Mackinnon, A.C.; Redfern, W.S. and Brown, C.M. (1995):** [³H]-RS-450041-190: a selective high-affinity radioligand for 12 imidazoline receptors. *Br. J. Pharmacol.*, 116 (2): 1729-1726.
- 255- **MacLennan, S. J.; Luong, L.A.; To, Z. P.; Jasper, J.R. and Eglén, R. M. (1997):** Characterization of alpha-2-adrenoceptors mediating contraction of dog saphenous vein: identity with the human- α_{2a} -subtype. *Br. J. Pharmacol.*, 121: 1721-1729.

- 256- Macphée, G. J.A.; Howie, C.A.; Elliott, H. L. and Reid, J. L. (1992): A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. *Br. J. Clin. Pharmacol.*, 33: 261-267.
- 257- Mangiameli, S.; Privitera, A.; Jonte, G. and Low-Kroger, A. (1992): Moxonidine Versus nifedipine retard in the treatment of mild to moderate hypertension. *Zietschrift fur allgemeinmedizin*, 68: 862-866.
- 258- Manolis, A. J.; Olympios, C. and Sifaki, M. (1995): Suppressing sympathetic activation in congestive heart failure: a new therapeutic strategy. *Hypertension*, 26: 719-724.
- 259- Marsault, R.; Taddei, S.; Boulanger, C. M.; Illiano, S. and Vanhoutte, P. M. (1996): Rilmenidine activates postjunctional α_2 -adrenoceptors in the canine saphenous vein. *Fundam. Clin. Pharmacol.*, 10: 379-385.
- 260- Maruna R.F.L. (1958). *Clin. Chem. Acta*, 2: 581
- 261- Masal, A.; Satta, G. and Alagna, S. (1985): Effects of clonidine on stress-induced cortisol release during surgery. *Pharmacol. Res. Communic.*, 17: 293-298.
- 262- Matsumura, Y.; Taira, S.; Kitano, R.; Hashimoto, N. and Toshihiko, K. (1999): Selective antagonism of endothelin ET_A or ET_B receptor in renal hemodynamics and function of deoxycorticosterone acetate-salt-induced hypertensive rats. *Eiol. Pharm. Bull.*, 22(8): 858-862.
- 263- Mayer, D. J. and Liebskind, J.C. (1974): Pain reduction by focal electrical stimulation of the brain: Anatomical and behavioural analysis *Brain Res.*, 68: 73-93.
- 264- Maze, M. and Smith, C. M. (1983): Identification of receptor mechanism mediating epinephrine-induced arrhythmias during halothane anesthesia in dogs. *Anesthesiology*, 59: 322-326.
- 265- Maze, M. and Tranquilli, W. (1991): Alpha-2-adrenoceptor agonists: Defining the role in clinical anesthesia. *Anesthesiology*, 74: 581-605.

- comparison to clonidine and GHRH. *Acta Endocrinologica*, 120 (suppl.1): 80-81.
- 276- **Mimran, A. and Ribstein, J. (1999):** Angiotensin Receptor blockers: Pharmacology and clinical significance. *J. Am. Soc. Nephrol.*, 10 (Suppl. 12): S 273-S 277.
- 277- **Minson, J.; Chalmers, J. and Drolet, G.; (1989):** Central serotonergic mechanisms in Cardiovascular regulation. *Cardiovasc. Drugs, Ther.* 4: 27-32.
- 278- **Mitrovic, V.; Patyna, W.; Huting, J. and Schlepper, M. (1991):** Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. *Cardiovasc Drugs and Therapy*, 5: 967-972.
- 279- **Mitrovic, V.; Hamel, M.; Miric, M.; Hamm, C. and Thormann, J. (2001):** Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. *Zkardiol.*, 90(12): 953-63.
- 280- **Molderings, G. J. (1995):** Imidazoline receptors. *Pharmacologic Principles and Physiologic and Therapeutic Significance Med. Monatsschr Pharm.*, 18 (7): 185-193.
- 281- **Molderings, G. J.; Hentrich, F. and Gothert, M. (1991):** Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 344: 630-638.
- 282- **Molderings, G. J.; Moura, D.; Fink, K.; Bonisch, H. and Gothert, M. (1993):** Binding of [^3H] clonidine to I_1 -imidazoline sites in bovine adrenal medullary membranes. *Naunyn Schmiedeberg's Arch-Pharmacol.*, 348: 70-76.
- 283- **Molderings, G.J.; Kundt, L. and Gothert, M. (1994):** [^3H] idazoan binding to bovine adrenal medullary membranes: identification and pharmacological characterization of I_2 -imidazoline sites. *Naunyn Schmiedeberg's Arch. Pharmacol.*, 350: 252-257.

- 284- **Molderings, G. J.; Donecker, K. and Gothert, M. (1995):** Characterization of non-adrenergic [^3H] clonidine binding sites in rat stomach: high affinity of imidazolines, guanidines and sigma ligands. *Naunyn Schmiedebergs Arch Pharmacol.*, 351: 561-564.
- 285- **Molderings, G. J.; Burian, M. and Menzel, S. (1999):** Imidazoline recognition sites and stomach function. *Ann. NY Acad. Sci.*, 881: 332-343.
- 286- **Monroe, P. J.; Smith, D. L.; Kirk, H.R. and Smith, D. J. (1995):** Spinal nonadrenergic imidazoline receptors do not mediate the antinociceptive action of intrathecal clonidine in the rat. *J. Pharmacol. Exp. Ther.*, 273: 14057-1062.
- 287- **Moreau, R.; Cailmail, S. and Lebrec, D. (1994):** Effects of vasopressin on hemodynamics in portal hypertensive rats receiving clonidine *Liver*, 14(1): 45-49.
- 288- **Morris, S. T. and Reid, J. L.; (1997):** Moxonidine: A review. *J. Hum. Hypertens.*, 11: 629-635.
- 289- **Morrison, P. J.; Corcoran, C. and Vivet, P. (1990):** Effect of rilmenidine on alertness. *JAMA*, July: 27-28.
- 290- **Motz, W.; Ippisch, R. and Strauer, B.E. (1983):** The role of clonidine in hypertensive heart disease. Influence on myocardial contractility and left ventricular afterload. *Chest*, 835: 433s. 435s.
- 291- **Motz, W.; Scheler, S. and Mox, B. (1998):** The potential clinical application of moxonidine in congestive heart failure. *Rev. Contemp. Pharmacother.*, 9: 473-479.
- 292- **Mukaddam-Daher, S. and Gutkowska, J. (2000):** Atrial natriuretic peptide is involved in renal actions of moxonidine. *Hypertension*, 35(6): 1215-20.
- 293- **Muller, M.; Weimann, H. J. and Weber, W. (1993):** Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide, *Eur. J. Drug Metab. Pharmacokinet.*, 18: 277-283.
- 294- **Murata, K.; Nakagawa, I.; Kumeta, Y.; Kitahata, L. M. and Collins, J.G. (1989):** Intrathecal clonidine suppresses

- noxiously evoked activity of spinal wide dynamic range neurons in cats. *Anesth-Analg.*, 62(2): 185-91.
- 295- **Nechifor, M. (2001):** Imidazoline receptors-normal and pathological factors. *Rev. Med. Chir. Soc. Med. Nat. Iasi.*, 105 (3): 438-443.
- 296- **Nichols, A. J. (1991):** Alpha-adrenoceptor signal transduction mechanisms, alpha-adrenoceptors. In: Ruffolo, R.R. Jr., ed. *Molec. Biol. Biochem. Pharmacol.* New York: Karger: 44-74.
- 297- **Nishijo, M.; Nakagawa, H. and Morikawa, Y. (1999):** Microalbuminuria and Hypertension in nondiabetic Japanese men. *Am. J. Hypertens.*, 12: 16.
- 298- **Nurminen, M. L. (1999):** Central nervous system as a target for the new antihypertensive agents. *Duodecim*, 115 (20): 2267-2273.
- 299- **Nurminen, M. L.; Culman, J. Haass, M.; Chung, O.; Unger, T. (1998):** Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. *Eur. J. Pharmacol.*, 27, 362(1): 61-67.
- 300- **O'Donnell, C. J. and Kannel, W. B. (1998):** Cardiovascular risks of hypertension: Lessons from observational studies. *J. Hypertens.*, 16(Suppl): 3.
- 301- **Ogidigben, M. J.; Chu, T.C. and Potter, D.E. (1999):** Peripheral and central effects of naphazoline on ocular hydrodynamics. Involvement of imidazoline receptors, ANP, and Gi proteins. *Ann. NY Acad. Sci.*, 21; 881: 388-391.
- 302- **Oldenbroek, C. (1991):** Double-blind, placebo-controlled, multicenter parallel group prospectively randomized study of the antihypertensive effects of moxonidine in patients with essential hypertension. *Kali-Chemie. Report 5004.* Hannover: Kali-Chemie.
- 303- **Ollivier, J. P.; Christen, M. O. and Schafer, S.G. (1992):** Moxonidine: A second generation of centrally acting drugs. *J. Cardiovasc. Pharmacol.*, 20(Suppl.4): S 31-S36.

- 304- Olmos, G.; Almany, R. and Garcia-Sevilla, J.A. (1996): Pharmacological and molecular discrimination of brain I₂-imidazoline receptor subtypes. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 354: 709-716.
- 305- Olsson, J. M. and Pruitt, A. W. (1983): Management of clonidine ingestion in children. *J. Pediatr.*, 103: 646-650.
- 306- Ongioco, R.R.; Richardson, C.D.; Rudner, X. L.; Stafford-Smith, M. and Schwinn, D.A. (2000): Alpha-2-adrenergic receptors in human dorsal root ganglia: Predominance of alpha 2b and alpha 2c subtype mRNAs. *Anesthesiology*, 92(4): 968-976.
- 307- Ooi, R.; Pattison, J. and Feldman, S.A. (1991): The effects of intravenous clonidine on ventilation. *Anaesthesia*, 46: 632-633.
- 308- Oparil, S. (1999): Treating multiple-risk hypertensive populations. *Am. J. Hypertens.*, 12: 121S-129S.
- 309- Oparil, S. (2000): Newly emerging pharmacologic differences in angiotensin II receptor blockers. *Am. J. Hypertens.*, 13: 18S-24S.
- 310- Opie, L. H. (1988): Sympathetic stimulation of ischemic myocardium: Role of plasma free fatty acids and potassium. *J. Cardiovasc. Pharmacol.*, 12 (Suppl.1): 531-538.
- 311- Opie, L. H.; Frishman, W. H. and Thadani, U. (1995): Calcium channel antagonists. In : *Drugs for the Heart*, Opie, L. H. (ed) 4th ed, Philadelphia, Saunders, pp.50-83.
- 312- Ordener, C.; Greney, H.; Bevedjian, J.; Dontenwill, M.; Bousquet, P. and Parini, A. (1999): Transfected cells expressing the three subtypes of alpha 2-adrenergic receptors lack I₁-imidazoline binding sites. *Ann. NY Acad. Sci.*, 21; 881: 59-60.
- 313- Orko, R.; Pouttu, J. and Ghignone, M. (1987): Effects of clonidine on hemodynamic responses to endotracheal intubation and on gastric acidity. *Acta Anaesthesiol. Scand.*, 31: 325-329.

- 314- Ossipov, M. H.; Suarez, L. J. and Spaulding, T.C. (1989): Antinociceptive interactions between alpha-2-adrenergic and opiate agonists at the spinal level in rodents *Anesth. Analg.*, 68(3): 194-200.
- 315- Otake, K., Ruggiero, D.A., Regunathan, S., Wang, H. and Reis, D. J. (1998): Regional localization of agmatine in the rat brain: An Immunocytochemical study. *Brain Res*, 16; 787(1): 1-14.
- 316- Paalzow L. (1974): Analgesia produced by clonidine in mice and rats. *J. Pharmacy Pharmacol.*, 26: 361-363.
- 317- Pabst, G.; Weimann, H. J. and Weber, W. (1992): Lack of pharmacokinetic interactions between moxonidine and digoxin. *Clin. Pharmacokinet.*, 23: 477-481.
- 318- Palkhiwala, S.A.; Yu, A. and Frishman, W. H. (2000): Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure. *Heart Dis.*, 2(1): 83-92.
- 319- Pan, H. L.; Chen, S.R. and Eisenach, J.C. (1998): Role of spinal NO in antiallodynic effect of intrathecal clonidine in Neuropathic rats. *Anesthesiology*, 89 (6): 1518-1523.
- 320- Parini. A., Coupry, I., Graham, R.M., Uzielli, I., Lanier, S. M. (1989): Characterization of an imidazoline / guanidinium receptive site distinct from the alpha-2-adrenergic receptor. *J. Biol. Chem.*, 264: 11874-78.
- 321- Parkin, M. L.; Godwin, S.J. and Head, G.A. (2003): Importance of imidazoline-Preferring receptors in the cardiovascular actions of chronically administered moxonidine, rilmenidine and clonidine in conscious rabbits. *J. Hypertens.*, 21(1): 167-178.
- 322- Pedrinelli, R.; Giampietro, O. and Carmassi, F. (1994): Microalbuminuria and endothelial dysfunction in essential hypertension. *Lancet*, 344: 14-17.
- 323- Penner, S. B. and Smyth, D.D. (1994): Sodium excretion following central administration of an I₁-imidazoline receptor agonist, moxonidine. *Br. J. Pharmacol.*, 112: 1089-1094.

- 324- **Pettinger, W.A. (1987):** Renal alpha-2-adrenergic receptors and hypertension. *Hypertension*, 9: 3-6.
- 325- **Petursson, G.; Cole, R. and Hanna, C. (1984):** Treatment of glaucoma using minidrops of clonidine. *Archives of Ophthalmology*, 101: 1180-1181.
- 326- **Piletz, J.E. and Sletten, K. (1993):** Nonadrenergic imidazoline binding sites on human platelets. *J. Pharmacol. Exp. Ther.*, 367: 1493-1502.
- 327- **Piletz, J.E.; Andorn, A.C.; Unnerstall, J.R. and Halaris, A. (1991):** Binding of [³H]-p-aminoclonidine to alpha-2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes. *Biochem. Pharmacol.*, 42: 569-584.
- 328- **Piletz, J.E.; Zhu, H. and Chikkala, D.N., (1996):** Comparison of ligand binding affinities at human I₁-imidazoline binding sites and the high affinity state of alpha-2-adrenoceptor subtypes. *J. Pharmacol. Exp. Ther.*, 279: 694-702.
- 329- **Piletz, J.E.; Zhu, H.; Ordway, G.; Stockmeier, C.; Dilly, G.; Reis, D. and Halaris, A. (2000):** Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. *Biol. Psychiatry*, 1; 48 (9): 910-919.
- 330- **Pineda, J.; Ruiz-Ortega, J.A.; Ugedo, L. and Garcia-Sevilla, J.A. (1995):** The stimulatory effect of clonidine on locus coeruleus noradrenergic neurons the imidazoline receptors is modulated by excitatory amino acids. *Ann. NY Acad. Sci.*, 12; 763: 501-505.
- 331- **Planitz, V. (1986):** Intraindividual comparison of moxonidine and prazosin in hypertensive patients. *Eur. J. Clin. Pharmacol.*, 39: 645-650.
- 332- **Planitz V. (1987):** Comparison of moxonidine and clonidine HCl in treating patients with hypertesion. *J. Clin. Pharmacol.*, 27: 46-51.
- 333- **Plant, T.D.; Jonas, J.C. and Henquin, J.C. (1991):** Clinidine inhibits ATP-sensitive K⁺ channels in mouse pancreatic β -cells. *Br. J. Pharmacol.*, 104: 385-390.

- 334- **Poisson, D.; Christen, M. O. and Sannajust, F. (2000):** Protective effects of I₁-antihypertensive agent moxonidine against neurogenic cardiac arrhythmias in halothane-anesthetized rabbits. *J. Pharmacol. Exp. Ther.*, 293: 929-938.
- 335- **Prichard, B. N.C. (1994):** Clinical experience with moxonidine. *Cardiovasc. Drugs Ther.*, 8 (Suppl. 1): 49-58.
- 336- **Prichard, B. N.C. (1996a):** Clinical experience with moxonidine. In: The I₁-imidazoline receptor agonist moxonidine: a new antihypertensive. Van Zwieten, P.A., Hamilton, C.A.; Julius, S.; and Prichard, B. N.C. (Eds) 2nd edition London. Royal society of medicine press, p 49-77.
- 337- **Prichard, B. N.C. (1996b):** Clinical pharmacology of moxonidine. In: The I₁-imidazoline receptor agonist moxonidine: a new antihypertensive. Van Zwieten, P.A.; Hamilton, C.A.; Julius, S. and Prichard, B. N.C. (Eds.). 2nd Edition. Roy. Soc. Med. Press London, p.31-47.
- 338- **Prichard, B. N.C.; Tomlinson, B. and Renondin, J.C. (1989):** Urapidil, a multiple action Alpha-blocking drug. *Am. J. Cardiol.*, 64: 11D-15D.
- 339- **Prichard, B. N.C.; Simmons, R.; Rooks, M. J. Haworth, D.A.; Laws, D. (1992):** A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. *J. Cardiovas. Pharmacol.*, 20 (suppl.4): 545-549.
- 340- **Prichard, B.N.; Owens, C.W.; Graham, B.R. (1997):** Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. *J. Hum. Hypertens.*, 11 (suppl.1): 529-545.
- 341- **Prichard, B.N.C.; Graham, B.R.; and Owens, W.C. W. I. (1999):** Moxonidine: A new antiadrenergic antihypertensive agent. *J. Hypertens.*, 17(suppl.3): 541-554.
- 342- **Prichard, B. N. C. and Graham, B.R. (2000):** I₁-imidazoline agonists. General clinical pharmacology of imidazoline receptors implications for the treatment of the elderly. *Drugs-Aging*, 17(2): 133-159.

- 343- Prichard, B. N. C.; Jager, B.A.; Luszick, J. H.; Kuster, L. J.; Verboom, C. N.; Hughes, P.R.; Sauermann, W. and Kuppers, H.E. (2002): Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. *Blood Press.*, 11(3): 166-172.
- 344- Przesmycki, K.; Dzieciuch, J.A.; Czuczwar, S. J. and Kleinrok, Z. (1999): Nitric oxide modulates spinal antinociceptive effect of clonidine but not that of baclofen in the formalin test in rats. *Eur. Neuropsychopharmacol.*, 9(1-2): 115-121.
- 345- Puke M.J.C. and Wiesenfeld-Hallin Z. (1993): The differential effects of morphine and the alpha-2 adrenoceptor agonist clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain. *Anesth Analg.*, 77: 104-109.
- 346- Puschett, J. B. (2000): Diuretics and the therapy of hypertension. *Am. J. Med. Sci.*, 319(1): 1-9.
- 347- Raasch, W.; Regunathan, S.; Li, G. and Reis, D. J. (1995): Agmatine, the bacterial amine, is widely distributed in mammalian tissues. *Life Sci.*, 56: 2319-2330.
- 348- Raasch, W.; Julian Chung, K.R.; Dendorfer, A. and Dominiak, P. (2000): Positive inotropic effects of imidazoline derivatives are not mediated via imidazoline binding sites but α_1 -adrenergic receptors. *Jpn. J. Pharmacol.*, 84: 1-6.
- 349- Raasch, W.; Schafer, U.; Chun, J. and Dominiak, P. (2001): Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. *Br. J. Pharmacol.*, 133 (6): 755-80.
- 350- Raasch, W.; Schafer, U.; Qadri, F. and Dominiak, P. (2002): Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction. *Br. J. Pharmacol.*, 135 (3): 663-672.
- 351- Raasch, W.; Jungbluth, B.; Schafer, U.; Hauser, W. and Dominiak, P. (2003): Modification of noradrenaline release in pithed spontaneously hypertensive rats by I_1 -binding sites in addition to α_2 -adrenoceptors. *J. Pharmacol., Exp. Ther.* 304(3): 1063-71.

- 352- **Radomski, M.W.; Palmer, R. M. and Moncada, S. (1987):** The anti-aggregating properties of vascular endothelium: interaction between prostacyclin and nitric oxide. *Br. J. Pharmacol.*, 92: 639-646.
- 353- **Rahman, M. M.; Varghese, Z.; Fuller, B. J. and Moorhead, J.F. (1999):** Renal vasoconstriction induced by oxidized LDL is inhibited by scavengers of reactive oxygen species and L-arginine. *Clin. Nephrol.*, 51: 98-107.
- 354- **Rahman, M. M.; Varghese, Z. and Moorhead, J.F. (2001):** Paradoxical increase in nitric oxide synthase activity in hypercholesterolaemic rats with impaired renal function and decreased activity of nitric oxide. *Nephrol. Dial. Transplant.*, 16: 262-268.
- 355- **Rahn, K.H.; Barenbrock, M. and Hausberg, M. (1999):** The sympathetic nervous system in the pathogenesis of hypertension *J. Hypertens.*, 17 (Suppl 3): 511-514.
- 356- **Ramage A. G. (1991):** The mechanism of the sympathoinhibitory action of urapidil: Role of 5-HT_{1A}-receptors. *Br. J. Pharmacol.*, 102: 998-1002.
- 357- **Ramage, A.G. and Wilkinson, S. J. (1989):** Evidence that different regional sympathetic outflows vary in their sensitivity to the sympathoinhibitory actions of putative 5-HT_{1A} and α_2 -adrenoceptor agonists in anaesthetized cats. *Br. J. Pharmacol.*, 98: 1157-1164.
- 358- **Randall, L. O. and Selitto, J. J. (1957):** *Arch. Int. Pharmacodyn. Ther.*, 111: 409.
- 359- **Reaven, G. M.; Lithell, H. and Landsberg, L. (1996):** Hypertension and associated metabolic abnormalities, The role of insulin resistance and the sympathoadrenal system *N. Engl. J. Med.*, 334: 374-381.
- 360- **Regunathan S. and Reis D. J. (1996):** Imidazoline receptors and their endogenous ligands. *Ann. Rev. Pharmacol. Toxicol.*, 36: 511-544.
- 361- **Regunathan, S.; Evinger, M. J.; Meeley, M. P. and Reis, D. J. (1991a):** Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium

- influx in bovine adrenal chromaffin cells. *Biochem. Pharmacol.*, 42: 2011-2018.
- 362- **Regunathan, S.; Meeley, M. P. and Reis, D. J. (1991b):** Clonidine-Displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. *Mol. Pharmacol.*, 40 (6): 884-888.
- 363- **Regunathan S.; Feinstein D. L. and Reis D. J. (1993a):** Expression of nonadrenergic sites in rat cerebral cortical astrocytes. *Journal of Neuroscience Research*, 34: 681-8.
- 364- **Regunathan S.; Meeley M.P. and Reis D. J. (1993b):** Expression of nonadrenergic imidazoline sites in chromaffin cell and mitochondrial membranes of bovine adrenal medulla. *Biochemical pharmacology*, 45: 1667-75.
- 365- **Regunathan, S.; Youngson, C.; Wang, H. and Reis, D. J. (1995):** Imidazoline receptors in vascular smooth muscle and endothelial cells. *Ann. NY Acad. Sci.*, 12; 763: 580-590.
- 366- **Regunathan, S.; Nassir, Y.; Sundaram, K.; Vaughan, E.D.; Reis, D. J. and Felsen, D. (1996):** Expression of I₂-imidazoline receptors in rat prostate. Effect of castration and aging. *Biochem. Pharmacol.*, 23; 51(4): 455-459.
- 367- **Reid, J. L. (2000):** Rilmenidine: A clinical overview. *Am. J. Hypertens.*, 13 (6 pt 2): 106 S-111S.
- 368- **Reid, J. L. (2001):** Update on rilmenidine: Clinical benefits. *Am. J. Hypertens.*, 14 (11 pt 2): 322 S – 324 S.
- 369- **Reid, J. L.; Ziven, J.A. and Kopin, I. J. (1975):** Central and Peripheral adrenergic mechanisms in the development of corticosterone-saline hypertension in rats. *Circ. Res.*, 37: 569-79.
- 370- **Reis, D. J. and Regunathan, S., (1998a):** Agmatine: An endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. *J. of the Autonomic Nervous Sysem.*, 72: 80-85.
- 371- **Reis, D. J. and Regunathan, S., (1998b):** Agmatine: α -novel neurotransmitter? *Eur. J. Pharmacol.*, 331: 133-138.

- 372- **Riekkinen, P. Jr., Laakso, M. P. and Jakala, P. (1999):** Clonidine Imparis sustained attention and memory in Alzheimer's disease. *Neuroscience*, 92: 975-982.
- 373- **Ritz, E.; Amann, K. and Fliser, D. (1998):** The sympathetic nervous system and the kidney: Its importance in renal diseases. *Blood Press.*, (Suppl.3), 14-9.
- 374- **Robertson, J. I.S.; Scott, D.J.; and Ball, S.G. (1986):** The serotonin antagonist ketanserin in the treatment of clinical hypertension: A short review. *J. Hypertens.*, 4 (Suppl.5): S 119-S 121.
- 375- **Rosen, P.; ohly, P. and Gleichmann, H. (1997):** Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. *J. Hypertens.*, 15(suppl.1) 531-538.
- 376- **Ruffolo, R.R. Jr (1985):** Distribution and function of peripheral alpha 2-adrenoceptors on the cardiovascular system. *Pharmacol. Biochem. Behav.*, 22: 827-833.
- 377- **Ruffolo, R.R. Jr and Waddell, J.E. (1982):** Receptor interactions of imidazolines. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist. *J. Pharmacol. Exp. Ther.*, 222:29-36.
- 378- **Ruiz-Durantez, E.; Ruiz-Ortega, J.A.; Pineda, J. and Ugedo, L. (2002):** Effect of agmatine on locus coeruleus neuron activity: Possible involvement of nitric oxide. *Br. J. Pharmacol.*, 135 (5): 1152-8.
- 379- **Rupp, H. and Jacob, R. (1995):** Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target ? *Med. Hypotheses*, 44(3): 217-225.
- 380- **Rupp, H.; Turcani, M. and Jacob, R. (1993):** Caloric intake and radio telemetrically assessed high blood pressure. *Pharm. Pharmacol. Lett.*, 3: 103-106.
- 381- **Rupp, H.; Maisch, B. and Brilla, CG. (1996):** Drug Withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidine. *Cardiovasc. Drugs Ther.*, 10: 251-262.

- 382- Safar, M.E. (1989): Rilmenidine: A novel antihypertensive agent. *Am. J. Med.*, 87 (Suppl. 3C): 245-295.
- 383- Safar, M.E. (1994): Arteries in clinical hypertension. Philadelphia: Lippincott-Raven.
- 384- Salonen, M.; Reid, K. and Maze, M. (1992): Synergistic interaction between α_2 -adrenergic agonists and benzodiazepines in rats. *Anesthesiology*, 76: 1004-1011.
- 385- Sasaki, S. and Bunag, R.D. (1983): Hypothalamic lesion abolish cardiovascular responses to chronic saline injection. *Am. J. Physiol.*, 224: 751-771.
- 386- Saxena, P.R. and Villalón, C. M. (1990): Brain 5HT_{1A}-receptor agonism: A novel mechanism for antihypertensive action. *Trends pharmacol. Sci.*, 11: 95-96.
- 387- Schachter, M. (1999a): Moxonidine: A review of safety and tolerability after seven years of clinical experience. *J. Hypertens.*, 17 (Suppl.3) S 37-S39.
- 388- Schachter, M. (1999b): Metabolic effects of moxonidine and other centrally acting antihypertensives. *Diabetes obes. Metab.*, 1(6): 317-22.
- 389- Schachter, M.; Luszick, J.; Jager, B.; Verboom, C. and Sohlke, E. (1998): Safety and tolerability of moxonidine in the treatment of hypertension. *Drug-Saf.*, 19(3): 191-203.
- 390- Schaefer, H.G.; Toubanc, N. and Weimann, H. J. (1998): The pharmacokinetics of moxonidine. *Rev. Contemp. Pharmacother.*, 9: 481-490.
- 391- Schaefer, S.G., Kaan, E.G., Christen, M. O., Mest, H. J., Molderings, G. J. (1995): Why imidazoline receptor modulator in the treatment of hypertension. *Ann. NY Acad Sci.*, 763: 659-672.
- 392- Schaefer, U.; Raasch, W.; Qadri, F.; Chun, J. and Dominiak, P. (1999): Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats. *Ann. NY Acad. Sci.*, 881: 97-101.
- 393- Schaefer, U.; Burgdorf, C.; Engelhardt, A.; Kurz, T. and Richardt, G. (2002): Presynaptic effects of moxonidine in

- isolated buffer perfused rat hearts: Role of imidazoline-1 receptors and alpha-2-adrenoceptors. *J. Pharmacol. Exp. Ther.*, 303(3): 1163-1170.
- 394- **Schann, S.; Bruban, V.; Pompermayer, K.; Feldman, J.; Renard, P.; Scalbert, E.; Bousquet, P. and Ehrhardt, J.D. (2001):** Synthesis and biological evaluation of pyrolic isosteres of rilmenidine. Discovery of Cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4, 5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I₁-imidazoline receptor selective ligand with hypotensive activity *J. Med. Chem.*, 10; 44 (10): 1588-1593.
- 395- **Schlatter, E.; Ankorina-Stark, I.; Haxelmans, S. and Hohage, H. (1997):** Moxonidine inhibits Na⁺/H⁺ exchange in proximal tubule cells and cortical collecting duct. *Kidney Int.*, 52(2): 454-459.
- 396- **Schlicker, E.; Armah, I. B. and Gothert, M. (1990):** Central presynaptic α_2 -autoreceptors are involved in the blood pressure-lowering effect of moxonidine. *J. Cardiovasc. Pharmacol.*, 16: 15-22.
- 397- **Schoetensack, W.; Bruckschen, E.G. and Zech, K. (1983):** Urapidil. In *New Drugs Annual: Cardiovascular Drugs*. Schriabine, A., ed New York: Raven Press, p.19-48.
- 398- **Scholze, J. and Sharma, A. M. (2001):** Treatment of hypertension in obesity. *Herz.*, 26(3): 209-21.
- 399- **Schworer, H.; Munke, H.; Stockmann, F. and Ramadori, G. (1995):** Treatment of diarrhea in carcinoid syndrome with tropisetron and clonidine. *Am. J. Gastroenterol.*, 90: 645-648.
- 400- **Scott, B.A.; Lawrence, B.; Nguyen, H. H. and Meyer, W. J. (1987):** Aldosterone and Dexamethazone binding in human arterial smooth muscle cells. *J. Hypertens.*, 5: 739-744.
- 401- **Senard, J. M.; Langin, D.; Estan, L. and Paris, H. (1990):** Identification of alpha 2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cells. *Eur. J. Pharmacol.*, 191: 59-68.

- 402- Serban, D. N.; Nechifor, M. and Slatineanu, S. M. (2000): Implications of imidazolines and imidazoline receptors role at the vascular level. *Rev. Med. Chir. Soc. Med. Nat. Iasi.*, 104 (4): 37-44.
- 403- Serone, A. P. and Angus, J.A. (1999): Role of N-type calcium channels in autonomic neurotransmission in guinea-pig isolated left atria. *Br. J. Pharmacol.*, 127(4): 927-934.
- 404- Sevcik, J. and Masek, K. (1999): New, Modern, Centrally active antihypertensive agents in the treatment of essential hypertension. *Cas. Lek.*, 7, 138 (12): 359-362.
- 405- Sides, G.D.; Leschinger, M. I.; Walenta, R. and McNay, J. L. (1998): The tolerability and adverse event profile of moxonidine. *Rev. Contemp. Pharmacother.*, 9: 491-499.
- 406- Sjöholm, B.; Savola, J. M. and Scheinin, M. (1995): Noradrenergic binding of [3 H] atimpacezole in rat lung. A novel imidazole binding site? *Ann. NY Acad. Sci.*, 763: 66-77.
- 407- Smits, J.F. and Struyker-Boudier, H.A. (1991): Regional hemodynamic effects of rilmenidine and clonidine in the conscious spontaneously hypertensive rat. *Fundam. Clin. Pharmacol.*, 5(8): 651-661.
- 408- Smyth, D.D.; Allan, D.R.; Li, P. and Penner, S.B. (1992): Direct renal actions of moxonidine are distinct from renal alpha-adrenoceptors. *Fundam. Clin. Pharmacol.*, 6: 505.
- 409- Smyth, D.D.; Allan, D.R. and Penner, S. B. (1995): Renal I₁-imidazoline receptor-selective compounds mediate natriuresis in the rat. *J. Cardiovasc. Pharmacol.*, 26 (Suppl.2): 563-567.
- 410- Söderpalm B. and Engel, J.A. (1988): Biphasic effects of clonidine on conflict behaviour. Involvement of different alpha-adrenoceptors. *Pharmacol. Biochem. Beh.*, 30: 471-477.
- 411- Spencer, C. and Lip, G. (1999): Hypertension-Antihypertensive drugs. *The pharmaceutical Journal*, 263: 351-354.

- 412- Staessen, J.A.; Wang, J.G.; Birkenhager, W. H. and Fagard, R. (1999): Treatment with β -blockers for the primary prevention of the cardiovascular complications of hypertension. *Eur. Heart. J.*, 20: 11.
- 413- Storlein, L. H.; Jenkins, A. B.; Chisholm, D. J.; Pascoe, W.S.; Khouri, S. and Kraegen, E.W. (1991): Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and W-3 fatty acids in muscle phospholipid. *Diabetes.*, 40: 280-289.
- 414- Storm, D.S. and Webb, R.C. (1992): α -Adrenergic receptors and Ca^{2+} efflux in arteries from deoxycorticosterone acetate hypertensive rats. *Hypertension* 19: 734-738.
- 415- Struthers, A.D.; MacFadyen, R.; Fraser, C.; Robson, J. Morton, J. J. and Ezan, E. (1999): Nonadherence with angiotension-Converting enzyme inhibitor therapy: A comparison of different ways of measuring it in patients with chronic heart failure. *J. Am. Coll. Cardiol.*, 34 (7): 2072-7.
- 416- Su, R. B.; Li, J.; Li, X. and Qin, B. Y. (2001): Down-Regulation of MAO-B activity and imidazoline receptors in rat brain following chronic treatment of morphine. *Acta. Pharmacol. Sin.*, 22(7): 639-644.
- 417- Sugawara, A. M.; Miguel, T. T.; de-oliveira, L. B.; Menani, J.V.; De-Luca-Junior, L.A. (1999): Noradrenaline and mixed α -2-adrenoceptor / imidazoline-receptor ligands: Effects on sodium intake. *Brain-Res.*, 28; 839(2): 227-34.
- 418- Swedberg, K.; Bergh, C.H.; Dickstein, K.; McNay, J. and Steinberg, M. (2000): The effect of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. *J. Am. Coll. Cardiol.*, 35 (2): 398-404.
- 419- Swedberg, K.; Bristow, M.R.; Cohn, J.N.; Dargie, H.; Straub, M.; Wiltse, C. and Wright, T. J. (2002): Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. *Circulation*, 16; 105 (15): 1797-1803.

- 420- Swislocki, A. L.M.; Vestal, R.E.; Reaven, G. M. and Hoffman, B. B. (1993): Acute metabolic effects of clonidine and adenosine in man. *Horm Metab. Res.*, 25: 90-95.
- 421- Szabo, B. (2002): Imidazoline antihypertensive drugs: A critical review on their mechanism of action. *Pharmacol. Ther.*, 93(1): 1-35.
- 422- Szabo, B.; Fritz, T. and Wedzony, K. (2001): Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex. *Br. J. Pharmacol.*, 134 (2): 295-304.
- 423- Tasker, R.A. and Melzack, R. (1989): Different alpha-receptor subtypes are involved in clonidine-produced analgesia in different pain tests. *Life Sci.*, 44 (1): 9-17.
- 424- Tesson, F. and Parini, A. (1991): Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. *Eur. J. Pharmacol.*, 208: 81-83.
- 425- Tesson, F., Prip-Buus, C., Lemoine, A., Pegorier, J. P. and Parini, A. (1991): Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the outer mitochondrial membrane. *J. Biol. Chem.*, 266:155-160.
- 426- Tesson, F., Prip-Buus, C., Lemoine, A., Pegorier, J. P. and Parini, A. (1992): Characterization of mitochondrial imidazoline guanidinium receptive sites (IGRS) in liver. *Am. J. Hypertension.*, 5: 580-582.
- 427- Theodor, R.A.; Weimann, H. J.; Weber, W. and Michaelis, K. (1991): Absolute bioavailability of moxonidine. *Eur. J. Drug. Metab. Pharmacokinet.*, 16: 153-159.
- 428- Theodor, R.A.; Weimann, H. J.; Weber, W.; Muller, M. and Michaelis, K. (1992): Influence of food on the oral bioavailability of moxonidine. *Eur. J. Drug. Metab. Pharmacokinet.*, 17: 61-66.

- 429- Theodor, R.A.; Weimann, H. J.; Muller, M.; Mosberg, H. and Michaelis, K. (1996): Age-related effects on the pharmacokinetics of moxonidine. *Eur. J. Clin. Res.*, 8: 63-74.
- 430- Thomas, G. P. and Stephen, P. M. (1991): Protective action of clonidine against the arrhythmogenic and lethal effects of ouabain in guinea-pigs. *Br. J. Pharmacol.*, 104: 995-999.
- 431- Thomas, G. P. and Tripathi, R. M. (1985): Effects of alpha-adrenoceptor agonists and antagonists on ouabain-induced arrhythmias and cardiac arrest in guinea-pig. *Br. J. Pharmacol.*, 89: 385-388.
- 432- Thoolen, M. J. MC.; Timmermans, P. B. M. and Van Zwieten, P.A. (1983): Withdrawal phenomena of some centrally acting anti-hypertensive drugs in the rat. *Br. J. Clin. Pharmacol.*, 15: 491S-505S.
- 433- Timmermans, P. B. M. and Van Zwieten, P.A. (1982): α_2 -adrenoceptors: Classification, localization, mechanisms, and targets for drugs. *J. Med. Chem.*, 25(12): 1389-1401.
- 434- Tolentino-Silva, F.P.; Haxhiu, M.A.; Waldbaum, S.; Dreshaj, J.A.; Ernsberger, P. (2000): Alpha-2-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice. *Brain-Res.*, 17, 862 (1-2): 26-35.
- 435- Toring, J.; Amann, K.; Ritz, E.; Nichols, C.; Zeier, M. and Mall, G. (1996): Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. *J. Am. Soc. Nephrol.*, 7(5): 667-675.
- 436- Tsoli, E.; Chan, S. L. and Morgan, N.G. (1995): The imidazoline I₁-receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islet's of langerhans. *Eur. J. Pharmacol.*, 284: 199-203.
- 437- Udvary, E.; Schafer, S.G.; Vegh A. and Szekeres, L. (1990): Haemodynamic effects of a new centrally acting antihypertensive agent moxonidine as compared to clonidine-*Eur. J. Pharmacol.*, 183: 2064.
- 438- Ueno, Y.; Mohara, O.; Brosnihan, K. B. and Ferrario, C. M. (1988): Characteristics of hormonal and neurogenic

- mechanisms of deoxycorticosterone-induced hypertension. *Hypertension*, 11 (Suppl. 1): 1172-177.
- 439- Ullian, M.E.; Islam, M. M.; Robinson, C. J.; Fitzgibbon, W.R.; Tobin, E.T. and Paul, R.V. (1997): Resistance to mineralocorticoids in Wistar-Furth rats. *Am. J. Physiol.*, 272: 111454-111461.
- 440- Van-den-Thillart, G.; Vianen, G.; Vianen, G.; Ponce, M.C.; Lelieveld, H.; Nieveen, M.; Zaagsma, J. (2001): Differential role of adrenoceptors in control of plasma glucose and fatty acids in carp. *Am. J. Physiol. Regul. Integr. Comp. Physiol.*, 281(2): R615-624.
- 441- Van Kerckhoven, R.; Saxena, P.R. and Schoemaker, R.G. (2002): Restored capillary density in spared myocardium of infarcted rats improves ischemic tolerance. *J. Cardiovasc. Pharmacol.*, 40(3): 370-380.
- 442- Van Nueten, J. M.; Janseen, P.A. J.; Van Beek, J.; Xhonneux, R.; and Vanhoutte, P. M. (1981): Vascular effects of ketanserin, a novel antagonist at 5-HT₂-serotonergic receptors. *J. Pharmacol. Ther.*, 218: 217-230.
- 443- Van. Zwieten, P.A. (1986): Overview of α_2 -adrenoceptor agonists with a central action. *Am J. Cardiol.*, 57: 3E-5E.
- 444- Van Zwieten, P.A. (1989a): Different types of centrally acting anti-hypertensive drugs. *Eur. Heart. J.*, 3: 121-133.
- 445- Van Zwieten, P.A. (1989b): Pharmacologic profile of urapidil. *Am. J. Cardiol.*, 64: 1D-6D.
- 446- Van Zwieten, P.A. (1992): Different types of centrally acting antihypertensive drugs. *Eur. Heart. J.*, 13 (suppl.A): 18-21.
- 447- Van, Zwieten, P.A. (1996): From alpha and beta to I₁: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. *J. Cardiovasc. Pharmacol.*, 27 (suppl.3): 55-510.
- 448- Van Zwieten, P.A. (1997): Centrally acting antihypertensives: A renaissance of interest mechanisms and haemodynamics. *J. Hypertens.*, 15 (suppl.1): 53-58.

- 449- **Van Zwieten, P.A. (1999):** Centrally acting antihypertensive drugs: Present and future. *Clin. Exper. Hypertens.*, 21 (5 & 6): 859-873.
- 450- **Van Zwieten, P.A. (2000):** Renewed interest in centrally acting antihypertensive drugs. *Cardiovasc. J.S. Afr.*, 11(4): 22S-229.
- 451- **Van Zweiten P.A. and Chalmers J. P. (1994):** Different types of centrally acting antihypertensives and their targets in the central nervous system. *Cardiovascular Drugs and Therapy*, 8: 787-799.
- 452- **Van Zwieten, P.A. and Peters, S. L. M. (1999):** Central I₁-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. *Ann, New York Acad. Sci.*, 881: 420-429.
- 453- **Van Zweiten, P.A.; Blawu, G. J.; and Van Brummelen, P. (1992):** Sertonegic receptors and drugs in hypertension. *Pharmacol. Toxicol.*, 70(suppl.II): 517-522.
- 454- **Vasan, R.S. and Levy, D. (1996):** The role of hypertension in the pathogenesis of heart failure. *Arch. Intern. Med.*, 156: 1789.
- 455- **Verdecchia, P.; Schillaci, G. and Borgioni, C. (1998):** Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation*, 97: 48.
- 456- **Vidt, D.G.; Gifford, R.W. and Vlasses, P. (1984):** A compendium for the treatment of hypertensive emergencies. *Clin. J. Med. Q.*, 15: 421.
- 457- **Vogel. P. et al. (1990):** *Clin. Chem.*, 36: 1070.
- 458- **Wang, H., Regunathan, S., Meeley, M. P. and Reis, D. J. (1992):** Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells. *Mol. Pharmacol.*, 42: 792-801.
- 459- **Wang, H., Regunathan, S., Ruggiero, D.A., and Reis, D.J. (1993):** Production and characterization of antibodies specific for the imidazoline receptor protein. *Mol. Pharmacol.*, 43: 509-515.

- 460- Waters, J.; Ashford, J. Jager, B.; Wonnacott, S. and Verboom, C. N. (1999): Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension. *J. Clin. Basic. Cardiol.*, 2: 219-224.
- 461- Watkins, J.; Fitz Gerald, G. and Zambouis, C. (1980): Absence of opiate and histamine H₂ receptor-mediated effects of clonidine lin. *Pharmacol. Ther.*, 28: 605-610.
- 462- Weber, K.; Bohmeke, R.; Vander Does, R. and Taylor, S. H. (1998): Hemodynamic differences between metoprolol and carvediolol in hypertensive patients. *Am. J. Hypertens.*, 11: 614-617.
- 463- Weber, M.A. (1980): Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents. *J. Cardiovasc. Pharmacol.*, 2(Suppl.1): 573-589.
- 464- Webster, J. and Koch, H.F. (1996): Aspects of tolerability of centrally acting antihypertensive drugs. *J. Cardiovasc. Pharmacol.*, 27 (Suppl.3): S49-S54.
- 465- Weimann, H. J. and Rudolph, M. (1992): Clinical pharmacokinetic of moxonidine. *J. Cardiovac. Pharmacol.*, 20 (suppl.4): 37S-41S.
- 466- Weisser, B.; Locher, R.; De Graaf, J. and Vetter, W. (1993): Low-density lipoprotein subfractions and $[Ca^{++}]$ in vascular smooth muscle cells. *Cir. Res.*, 73: 118-124.
- 467- Wenzel, R.R.; Spieker, L.; Qui, S.; Shaw, S.; Luscher, T.F. and Noll, G. (1998): I₁-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. *Hypertension*, 32 (6): 1022-1027.
- 468- Wesnes, K.; Simpson, P. M.; Jansson, B.; Grahnen, A.; Weimann, H. J. and Kueppers, H. (1997): Moxonidine and cognitive function: interactions with moclobemide and lorazepam. *Eur. J. Clin. Pharmacol.*, 52: 351.
- 469- Wethmar, U.; Raasch, W.; Dendorfer, A. and Dominiak, P. (2001): Interactions of ligands at angiotensin II-receptors and imidazoline receptors. *Jpn. J. Pharmacol.*, 85(2): 167-174.

- 470- **White, W. B. (2000):** Benefits of antihypertensive therapy in older patients with hypertension. *Arch. Intern. Med.*, 160: 149-150.
- 471- **Whitsett, T. L. (1983):** Abrupt cessation of treatment with centrally acting antihypertensive agents: a review. *Chest*, 83 (suppl.): 400-402.
- 472- **Wiecek, A.; Fliser, D.; Nowicki, M. and Ritz, E. (1995):** Effect of moxonidine on urinary electrolyte excretion and renal hemodynamics in man. *Eur. J. Clin. Pharmacol.*, 48: 203-208.
- 473- **Wiest, S.A. and Steinberg, M. I. (1999):** 3H [2-benzofuranyl]-2-imidazoline] (BFI) binding in human platelets: Modulation by tranilcypromine. *Naunyn-Schmiedeberg's Arch-Pharmacol.*, 360(2): 209-216.
- 474- **Wikberg, J.E. (1989):** High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: Description of a putative idazoxan-receptor. *Pharmacol., Toxicol.* 64: 152-155.
- 475- **Wilkens, H.; Wilkens, J. H. and Hecht, M. (1990):** Effect of moxonidine, an alpha 2 adrenergic agonist, on histamine-induced bronchial constriction and ventilatory and occlusion responses to carbon dioxide in asthmatics. Joint Meeting of the *societas Europaea physiologiae clinicae respiratorine (SEP-SEPCR)*, Sep 9-14; London.
- 476- **Williams, G. H. (1998):** Hypertensive vascular disease. In: *Harrison's principles of internal medicine*. Braunwald, E., Fauci, A.S., Wilson, J.D. and Martin J. B. (eds.). 14th ed. McGraw-Hill Book Company, Vol.1: p.1380-1394.
- 477- **Wirth, D.D.; He, M. M.; Czeskis, B. A.; Zimmerman, K. M.; Roewttig, U.; Stenzel, W. and Steinberg, M. I. (2002):** Identification, synthesis and pharmacological activity of moxonidine metabolites. *Eur. J. Med. Chem.*, 37 (1): 23-34.
- 478- **Wise, S.D.; Chan, C.; Schaefer, H.G.; He, M. M.; Pouliquen, I. J. and Mitchell. (2002):** Quinidine does not affect the renal clearance of moxonidine. *Br. J. Clin. Pharmacol.*, 54(3): 251-254.

- 479- Wober, W.; Szmatoch, E.; Gardosch Von Krosigk, P. P. and Hoflich, C. (1995): Influence of moxonidine and atenolol on the lipid metabolism of patients with mild to moderate hypertension. A randomized double-blind parallel group study. Kali Chemie AG., K220: 5032.
- 480- Wolf, R. (1992): The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison J. Cardiovasc. Pharmacol., 20 (Suppl.4): 542-544.
- 481- Wolk, R.; Kane, K.A.; Cobbe S. M. and Hicks, M. N. (1999): Facilitation of spontaneous defibrillation by moxonidine during regional ischaemia in an isolated working rabbit heart model. Eur. J. Pharmacol., 12; 367 (1): 25-32.
- 482- World Health Organization-International Society of Hypertension (1999): Guidelines for the management of hypertension. J. Hypertens., 17: 151.
- 483- Wouters, W.; Tulip, M.T.M. and Bevan, P. (1988): Flesinoxan lowers blood pressure and heart rate in cats via 5 HT_{1A}-receptors. Eur. J. Pharmacol., 149: 213-222.
- 484- Xu, Y. F. and He, R.R. (1997): Effects of moxonidine injected into rostral ventrolateral medulla on blood pressure, heart rate, and renal sympathetic nerve activity in rats Chung-Kuo-Yao-Li-Hsueh-Pao., 18(5): 415-418.
- 485- Xu, Z.; Chen, S.R.; Eisenach, J. and Pan, H. L. (2000): Role of spinal muscarinic and nicotinic receptors in clonidine-induced nitric oxide release in a rat model of neuropathic pain. Brain Res., 10; 861(2): 390-398.
- 486- Yablonsky, F. and Dausse, J. P. (1991): Non-adrenergic binding sites for the "alpha 2-antagonist" [³H] idazoxan in the rabbit urethral smooth muscle. Pharmacological and biochemical characterization. Biochem. Pharmacol., 41: 701-707.
- 487- Yakash T. L., Pogrel J.W. and Lee Y.W. (1995): Reversal of nerve ligation-induced allodynia by spinal alpha-2 adrenoceptor agonists. J. Pharmacol. Exp. Therap., 272: 207-214.

- 488- Yamaguchi, I. and Kopin, I. J. (1980): Differential inhibition of alpha-1 and alpha-2-adrenoceptor mediated pressor responses in pithed rats. *J. Pharmacol. Exp. Ther.*, 214: 275-281.
- 489- Yesilyrt, O. and Uzbay, I.T. (2001): Agmatine Potentiates the analgesic effect of morphine by an alpha (2)-adrenoceptor-mediated mechanism in mice. *Neuropsychopharmacol.*, 25(1): 98-103.
- 490- Youngson, C.; Regunathan, S.; Wang, H.; Li, G and Reis, D. J. (1995): Co-expression of imidazoline receptors and agmatine in rat carotid body. *Ann. NY Acad. Sci.*, 763: 440-444.
- 491- Zhu, Q. M.; Lesenick, J.D.; Jasper, J.R.; MacIennan, S.J.; Dillon, M. P.; Eglen, R. M. and Blue, D.R. (1999): Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha-2A-adrenoceptor transgenic mice. *Br. J. Pharmacol.*, 126(6): 1522-30.
- 492- Ziegler, D.; Haxhiu, M.A.; Kaan, E.C.; Papp, J.G. and Ernsberger, P. (1996): Pharmacology of moxonidine, an I₁-imidazoline receptor agonist. *J. Cardiovasc. Pharmacol.*, 27 (suppl.3), S26-S37.
- 493- Zink, M.; Gombotz, H.; Wasler, A.; Grasser, B.; Rehak, P. and Metzler, H. (2002): Urapidil reduces elevated pulmonary vascular resistance in patients before heart transplantation. *J. Heart Lung Transplant.*, 21 (3): 347-353.
- 494- Zonnenchein, R.; Diamant, S. and Atlas, D. (1990): Imidazoline receptors in rat liver cells: A novel receptor or a subtype of alpha-2-adrenoceptors. *Eur. J. Pharmacol.*, 190: 203-215.